{"gene":"TNFSF10","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":1995,"finding":"TRAIL (TNFSF10) was identified as a novel type II transmembrane protein of the TNF family, with its C-terminal extracellular domain forming a homotrimeric structure. Both full-length cell-surface TRAIL and picomolar concentrations of soluble TRAIL rapidly induce apoptosis in a wide variety of transformed cell lines. The TRAIL gene is located on chromosome 3q26.","method":"cDNA cloning, transfection/overexpression, apoptosis assays with recombinant soluble protein","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 1 — original cloning paper with biochemical characterization; foundational discovery replicated extensively","pmids":["8777713"],"is_preprint":false},{"year":1996,"finding":"Apo-2L (TRAIL/TNFSF10) is a 281-amino acid type II transmembrane protein whose C-terminal extracellular region forms a homotrimeric subunit structure. Soluble Apo-2L induces apoptosis in lymphoid and non-lymphoid tumor cell lines through a receptor distinct from Fas/Apo-1 and TNF receptors, as soluble Fas and TNF receptors do not inhibit its activity.","method":"Recombinant protein expression, apoptosis assays, receptor competition experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstitution with recombinant protein plus receptor competition assays; independent of PMID 8777713","pmids":["8663110"],"is_preprint":false},{"year":1997,"finding":"DR4 (TRAIL-R1), identified as the first receptor for TRAIL, is a member of the TNF-receptor family containing a cytoplasmic death domain capable of engaging the apoptotic machinery. DR4 could not use FADD to transmit the death signal (unlike Fas, TNFR-1, and DR3), suggesting use of distinct proximal signaling machinery. DR4 did not activate NF-κB in the system studied.","method":"Receptor cloning, death domain functional assays, FADD interaction studies, NF-κB reporter assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — receptor identification with functional domain characterization; highly cited foundational paper","pmids":["9082980"],"is_preprint":false},{"year":1997,"finding":"TRAIL-R2 (DR5) was identified as a distinct receptor for TRAIL via ligand-based affinity purification from human cell lines. TRAIL-R2 contains two extracellular cysteine-rich repeats and a cytoplasmic death domain. Unlike TRAIL-R1, TRAIL-R2 mediates apoptosis via the intracellular adaptor molecule FADD/MORT1. The TRAIL-R2 gene maps to chromosome 8p22-21.","method":"Ligand-based affinity purification, molecular cloning, FADD interaction assays, Fc fusion protein blocking experiments","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — protein purified directly from cell lines, cloned, and functionally characterized with multiple orthogonal methods","pmids":["9311998"],"is_preprint":false},{"year":1997,"finding":"TRID (TRAIL-R3/DcR1), an antagonist decoy receptor for TRAIL, was identified with an extracellular TRAIL-binding domain and transmembrane domain but no intracellular signaling domain. Ectopic expression of TRID protected cells from TRAIL-induced apoptosis. A second death domain-containing receptor DR5 preferentially engaged a FLICE (caspase-8)-related death protease.","method":"Gene cloning, ectopic expression, apoptosis protection assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — functional rescue experiment demonstrating decoy receptor mechanism; highly cited","pmids":["9242610"],"is_preprint":false},{"year":1997,"finding":"TRAIL-R2 (DR5) and TRAIL-R3 were characterized: TRAIL-R2 is structurally similar to TRAIL-R1 and capable of inducing apoptosis; TRAIL-R3 does not promote cell death, is highly glycosylated, and is membrane-bound via a GPI anchor. TRAIL-R3 has TAPE repeats extending its structure. All three receptors bind TRAIL with similar affinity.","method":"Receptor cloning, apoptosis assays, binding affinity measurements, glycosylation and GPI anchor characterization","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal biochemical methods characterizing receptor structure and function","pmids":["9373179"],"is_preprint":false},{"year":1997,"finding":"TRAIL-R4, a fourth TRAIL receptor, was cloned and characterized. TRAIL-R4 retains an incomplete death domain (one-third of consensus motif) and activates NF-κB similarly to TRAIL-R1/R2, but cannot induce apoptosis. Transient overexpression of TRAIL-R4 in TRAIL-sensitive cells conferred complete protection from TRAIL-mediated killing. TRAIL-R4 gene maps to chromosome 8p22-21, clustered with other TRAIL receptor genes.","method":"Gene cloning, NF-κB reporter assays, apoptosis assays, overexpression protection experiments","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — functional overexpression experiments with NF-κB and apoptosis assays; highly cited","pmids":["9430226"],"is_preprint":false},{"year":1997,"finding":"TRAIL-R1 (DR4) and TRAIL-R2 (DR5) both bind the adaptor molecules FADD and TRADD, and both death signals are blocked by dominant-negative FADD and by the FLICE-inhibitory protein FLIP. TRAIL-R1 can associate with TRAIL-R2, suggesting possible signaling through heteroreceptor complexes. Recruitment of TRADD explains the potent NF-κB activation observed from TRAIL receptors.","method":"Co-immunoprecipitation, dominant-negative FADD and FLIP overexpression, NF-κB reporter assays","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP plus genetic (dominant-negative) epistasis; highly cited","pmids":["9430228"],"is_preprint":false},{"year":1997,"finding":"Two additional TRAIL receptors, TRAIL-R2 (DR5, containing a death domain) and TRAIL-R3 (lacking a death domain), were identified. DR5 engages the apoptotic pathway independently of FADD/MORT1. TRAIL-R3, by competing for TRAIL binding, inhibits TRAIL-induced apoptosis, functioning as an antagonistic decoy receptor.","method":"cDNA library screening, apoptosis assays, FADD interaction studies, competition binding assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple functional assays establishing decoy mechanism; highly cited","pmids":["9325248"],"is_preprint":false},{"year":1997,"finding":"TRAIL-R3 (DcR1) was cloned and shown to be a GPI-linked plasma membrane protein with high-affinity TRAIL binding but lacking a cytoplasmic domain. TRAIL-R3 does not induce apoptosis and shows restricted expression in peripheral blood lymphocytes and spleen. The TRAIL-R3 gene maps to chromosome 8p22-21.","method":"cDNA cloning, quantitative binding studies, GPI-anchor characterization, apoptosis assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — biochemical characterization with quantitative binding and functional assays","pmids":["9314565"],"is_preprint":false},{"year":1999,"finding":"The crystal structure of the Apo2L/TRAIL homotrimer in complex with the ectodomain of DR5 was solved. Three elongated DR5 receptors bind in long crevices between pairs of monomers of the trimeric ligand. The binding interface is divided into two distinct patches (near the membrane-proximal and membrane-distal ends), both containing residues critical for high-affinity binding. Comparison to the lymphotoxin-receptor complex revealed general principles of binding in the TNF receptor superfamily.","method":"X-ray crystallography","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure; foundational structural paper","pmids":["10549288"],"is_preprint":false},{"year":2000,"finding":"FADD/MORT1 and caspase-8 are recruited to both TRAIL-R1 and TRAIL-R2 in a ligand-dependent manner to form the TRAIL death-inducing signaling complex (DISC). FADD/MORT1 and caspase-8 are recruited to the two TRAIL receptors independently of each other. FADD- and caspase-8-deficient Jurkat cells expressing only TRAIL-R2 were resistant to TRAIL-induced apoptosis, establishing that both proteins are essential for TRAIL-R2-mediated apoptosis.","method":"Native DISC immunoprecipitation, differential receptor precipitation, genetic knockout cell lines (FADD-deficient, caspase-8-deficient)","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — native DISC biochemistry combined with genetic KO cells; highly cited","pmids":["10894160"],"is_preprint":false},{"year":2002,"finding":"Caspase-10 is recruited to both the native TRAIL DISC and the native CD95 DISC in a FADD-dependent manner and is activated at these complexes. However, caspase-10 cannot functionally substitute for caspase-8: caspase-8-deficient cells could not be rescued by caspase-10 overexpression. Caspase-10 is cleaved during CD95-induced apoptosis of activated T cells.","method":"Native DISC immunoprecipitation, genetic knockout cells (FADD-deficient), caspase-10 overexpression rescue experiments, primary T cell assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — native DISC biochemistry plus genetic epistasis; well-controlled","pmids":["12198154"],"is_preprint":false},{"year":2002,"finding":"FOXO forkhead transcription factors FKHRL1 and FKHR directly regulate TRAIL (TNFSF10) expression. The FKHRL1-responsive element in the TRAIL promoter was mapped to nucleotides -138 to -121. Loss of PTEN in prostate cancer leads to decreased FOXO activity and reduced TRAIL expression in metastatic prostate tumors, linking the PI3K-Akt pathway to TRAIL gene regulation.","method":"Microarray gene expression, adenoviral FOXO overexpression, TRAIL promoter reporter constructs, chromatin analysis, human tumor immunohistochemistry","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — promoter mapping with deletion constructs plus in vivo tumor validation","pmids":["12351634"],"is_preprint":false},{"year":2002,"finding":"PPAR-γ ligands sensitize tumor cells (but not normal cells) to TRAIL-induced apoptosis by reducing FLIP protein levels through ubiquitination and proteasome-dependent degradation, without affecting FLIP mRNA. This mechanism is PPAR-γ-independent (active with both agonists and antagonists and dominant-negative PPAR-γ) and does not involve NF-κB.","method":"PPAR-γ agonist/antagonist treatment, dominant-negative PPAR-γ, FLIP ubiquitination assays, proteasome inhibitor experiments, mRNA vs. protein analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches ruling out PPAR-γ and NF-κB dependence and establishing ubiquitin-proteasome mechanism","pmids":["11940602"],"is_preprint":false},{"year":2004,"finding":"HDAC inhibitors induce TRAIL (TNFSF10) expression in acute myeloid leukemia (AML) cells by directly activating the TNFSF10 promoter, thereby triggering tumor-selective death signaling. RNA interference showed that TRAIL induction, p21 induction, and differentiation are separable activities of HDACIs. Normal CD34+ progenitor cells did not undergo apoptosis.","method":"HDAC inhibitor treatment, TRAIL promoter reporter assays, RNA interference (siRNA), chromatin immunoprecipitation, primary AML blast assays","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — promoter-level mechanistic evidence with RNAi and primary patient cells; highly cited","pmids":["15619633"],"is_preprint":false},{"year":2004,"finding":"FLIP protein potently blocks TRAIL-mediated cell death by interfering with caspase-8 activation at the DISC. Pharmacologic down-regulation of FLIP sensitizes tumor cells to TRAIL-induced apoptosis.","method":"FLIP overexpression and knockdown, caspase-8 activation assays, apoptosis assays","journal":"Vitamins and hormones","confidence":"Medium","confidence_rationale":"Tier 2 — review synthesizing mechanistic studies; single review paper without primary data","pmids":["15110178"],"is_preprint":false},{"year":2005,"finding":"TRAIL-receptor-selective mutant forms of TRAIL were synthesized that selectively bind TRAIL-R1 or TRAIL-R2. The selectivity in inducing apoptosis is due to selective receptor binding and formation of a death-inducing signaling complex (DISC) with the cognate receptor. Using these mutants, primary chronic lymphocytic leukemia and mantle cell lymphoma cells were shown to signal apoptosis almost exclusively through TRAIL-R1.","method":"Synthetic receptor-selective TRAIL mutants, apoptosis assays, DISC formation analysis, primary patient CLL and MCL cells","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — engineered mutant ligands with DISC biochemistry and primary patient cell validation","pmids":["16357130"],"is_preprint":false},{"year":2007,"finding":"O-glycosylation of death receptors DR4 and DR5 by the peptidyl O-glycosyltransferase GALNT14 controls tumor-cell sensitivity to Apo2L/TRAIL. Biochemical analysis identified O-(GalNAc-Gal-sialic acid) structures on the DR5 ectodomain at conserved extracellular sites. Progressive mutation of these sites attenuated apoptotic signaling. O-glycosylation promoted ligand-stimulated clustering of DR4 and DR5, which mediated recruitment and activation of caspase-8.","method":"GALNT14 RNAi and overexpression, DR5 mass spectrometry glycosylation mapping, site-directed mutagenesis of O-glycosylation sites, receptor clustering assays, caspase-8 activation assays","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 1 — biochemical glycan mapping plus mutagenesis plus functional clustering assays; highly cited","pmids":["17167167"],"is_preprint":false},{"year":2008,"finding":"The transcription factor Sp1 is responsible for TRAIL (TNFSF10) induction by the HDAC inhibitor MS275 alone or in combination with Adriamycin in breast cancer cells. Chromatin immunoprecipitation confirmed Sp1 binding to the TRAIL promoter. Knockdown of TRAIL by siRNA decreased MS275-mediated Adriamycin-induced caspase activation, and Sp1-knockout MEFs were resistant to combined treatment.","method":"TRAIL promoter reporter constructs, chromatin immunoprecipitation, Sp1 siRNA knockdown, Sp1-knockout mouse embryonic stem cells, caspase activation assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — promoter mapping with ChIP, RNAi, and genetic KO cells with multiple readouts","pmids":["18701496"],"is_preprint":false},{"year":2009,"finding":"TRAIL-induced autophagy in untransformed epithelial cells is mediated by AMPK, which inhibits mTORC1. TRAIL-induced AMPK activation is independent of LKB1 and CaMKK-β but depends on TAK1 and TAK1-binding subunit 2. This cytoprotective autophagy pathway contributes to the resistance of normal (untransformed) cells to TRAIL-induced apoptosis.","method":"Genetic knockdown (siRNA for TAK1, LKB1, CaMKK-β), AMPK activity assays, mTORC1 signaling assays, autophagy monitoring, apoptosis assays in normal vs. transformed cells","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — multiple RNAi knockdowns establishing epistasis; published in high-impact journal","pmids":["19197243"],"is_preprint":false},{"year":2009,"finding":"Death receptor ligation by TRAIL/DR4/DR5 induces polyubiquitination of caspase-8 through a cullin3 (CUL3)-based E3 ligase that is recruited to the DISC. CUL3-mediated caspase-8 polyubiquitination requires RBX1; the deubiquitinase A20 reverses this modification. The ubiquitin-binding protein p62/sequestosome-1 promotes aggregation of CUL3-modified caspase-8 within p62 foci, leading to full activation, processing, and commitment to apoptosis.","method":"Co-immunoprecipitation of native DISC, ubiquitination assays, CUL3/RBX1/A20/p62 RNAi knockdown, caspase-8 processing assays, confocal microscopy of p62 foci","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — mechanistic reconstitution with multiple orthogonal methods identifying a new PTM (ubiquitination) and its writer/eraser/reader; highly cited","pmids":["19427028"],"is_preprint":false},{"year":2003,"finding":"TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. TRAIL-R2 (but not TRAIL-R1, R3, or R4) is expressed throughout erythroid differentiation from CD34+ progenitors. TRAIL stimulates ERK1/2 (but not p38 MAPK or JNK) signaling in erythroblasts, and the ERK inhibitor PD98059 (but not the pan-caspase inhibitor z-VAD or p38 inhibitor SB203580) reverses the anti-differentiative effect of TRAIL on erythroid maturation.","method":"Flow cytometry (receptor expression), recombinant TRAIL treatment, ERK/p38/JNK phosphorylation assays, pharmacological pathway inhibitors, morphological differentiation assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — specific pathway inhibitors with selective pharmacological dissection; primary CD34+ cell system","pmids":["12969966"],"is_preprint":false},{"year":2010,"finding":"TRAIL-R4 expressed endogenously or ectopically inhibits TRAIL-induced apoptosis. Chemotherapy restores TRAIL sensitivity in TRAIL-R4-expressing cells primarily at the DISC level through enhanced caspase-8 recruitment and activation. The sensitization is compromised by c-FLIP expression and is independent of mitochondria. TRAIL-R4 cooperates with c-FLIP to inhibit TRAIL-induced cell death, and TRAIL-R4 expression prevents TRAIL-induced tumor regression in vivo.","method":"Ectopic TRAIL-R4 expression, DISC immunoprecipitation, caspase-8 recruitment assays, c-FLIP manipulation, mitochondria-independent cell death assays, xenograft tumor models","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 — native DISC biochemistry plus in vivo xenograft validation","pmids":["21072058"],"is_preprint":false},{"year":2014,"finding":"TRAF2 acts as a negative regulator of TRAIL-induced apoptosis and necroptosis. TRAF2 knockdown sensitizes keratinocytes to TRAIL-induced apoptosis. In cells lacking RIP3, TRAF2 knockdown sensitizes to TRAIL-induced caspase-dependent apoptosis. In RIP3-expressing cells, TRAF2 knockdown additionally sensitizes to TRAIL-induced necroptosis. TRAIL-induced necroptosis is independent of endogenous TNF/TNFR signaling. TWEAK-mediated depletion of cytosolic TRAF2 complexes strongly sensitizes for TRAIL-induced necroptosis.","method":"TRAF2 siRNA knockdown, zVAD-fmk (pan-caspase inhibitor) protection assays, necrostatin-1 (RIP1 inhibitor), RIP3-stable transfectants, TNFR2-Fc and anti-TNFα blocking experiments","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 — genetic knockdown combined with pharmacological inhibitors and RIP3 reconstitution system dissecting apoptosis vs. necroptosis","pmids":["25299769"],"is_preprint":false},{"year":2014,"finding":"DAPK2 (death-associated protein kinase 2) is a modulator of TRAIL signaling. Genetic ablation of DAPK2 by RNAi causes NF-κB phosphorylation and transcriptional activation, leading to induction of DR4 and DR5 expression. Increased DR4/DR5 surface expression sensitizes resistant cancer cells to TRAIL-induced killing in a p53-independent manner.","method":"DAPK2 siRNA knockdown, NF-κB reporter and phosphorylation assays, DR4/DR5 surface flow cytometry, p53-deficient cell lines, TRAIL cytotoxicity assays","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 — RNAi knockdown with pathway reporter and surface receptor quantification; single lab","pmids":["25012503"],"is_preprint":false},{"year":2015,"finding":"Poly-ADP-ribosylation of HMGB1 by PARP1 is required for TRAIL (TNFSF10)-induced HMGB1 cytoplasmic translocation and subsequent HMGB1-BECN1 complex formation, which drives cytoprotective autophagy. Pharmacological inhibition or knockdown of PARP1 inhibits HMGB1-mediated autophagy, increases apoptosis, and enhances TRAIL anticancer activity in vitro and in a tumor model. Thus PARP1-dependent HMGB1 ADP-ribosylation maintains a homeostatic balance between autophagy and apoptosis during TRAIL signaling.","method":"PARP1 pharmacological inhibition and siRNA knockdown, HMGB1 ADP-ribosylation assays, co-immunoprecipitation (HMGB1-BECN1 complex), autophagy monitoring, apoptosis assays, subcutaneous tumor model","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 2 — PTM identification (ADP-ribosylation) with Co-IP of downstream complex and in vivo validation","pmids":["25607248"],"is_preprint":false},{"year":2016,"finding":"Hepatitis B virus X protein (HBx) evades TRAIL (TNFSF10)-mediated antiviral immunity by promoting autophagy-mediated lysosomal degradation of TNFRSF10B (DR5). HBx directly interacts with TNFRSF10B and recruits it to phagophores (autophagosome precursors), acting as an autophagy receptor-like molecule that promotes TNFRSF10B association with LC3B. HBx also functions as an autophagy inducer. Inhibition of autophagy enhances susceptibility of HBx-infected hepatocytes to TRAIL.","method":"Immunoprecipitation and GST affinity isolation (HBx-TNFRSF10B interaction), tandem-fluorescence LC3B assay, LC3B/SQSTM1 immunoblotting, LC3B knockdown, pharmacological autophagy inhibition, liver tissue from chronic HBV patients","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 2 — direct protein interaction (GST pulldown + Co-IP) combined with autophagy functional assays and patient tissue validation","pmids":["27740879"],"is_preprint":false},{"year":2016,"finding":"TRAIL-mediated necroptosis shares signaling components with TNF-mediated necroptosis including acid and neutral sphingomyelinases, HtrA2/Omi, Atg5, and vacuolar H+-ATPase. However, TRAIL-mediated necroptosis differs from TNF-mediated necroptosis in being independent of UCH-L1 and Atg16L1, and does not require receptor internalization or endosome-lysosome acidification. Bcl-XL overexpression specifically diminishes TRAIL-induced necroptosis, suggesting differential mitochondrial involvement. Depletion of p38α increases both types of cell death.","method":"siRNA knockdown of signaling components, pharmacological inhibitors, Bcl-2/Bcl-XL overexpression, RIP3-expressing cell systems, necroptosis quantification","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 — systematic siRNA screen combined with overexpression experiments in defined cell systems","pmids":["27528614"],"is_preprint":false},{"year":2019,"finding":"DR4 (TRAIL-R1) is O-GlcNAcylated at Ser424 within its death domain, and this modification is essential for TRAIL-induced apoptosis and necrosis. Ser424 mutations identified from cancer patients caused TRAIL resistance. O-GlcNAcylation-defective DR4 failed to form DISC/necrosome and could not translocate to aggregated receptor-clustering platforms. DR5 is not O-GlcNAcylated by TRAIL treatment, discriminating DR4 from DR5-mediated signaling. Promoting DR4 O-GlcNAcylation (with 2-deoxy-D-glucose or high glucose) sensitized resistant cancer cells to TRAIL.","method":"O-GlcNAc transferase knockdown, DR4 site-directed mutagenesis (Ser424), cancer patient cDNA library screen (TCGA), DR5-neutralizing antibody, DISC/necrosome co-immunoprecipitation, receptor clustering assays, glucose-modulated O-GlcNAcylation","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 — identifies a novel PTM (O-GlcNAcylation) on TRAIL-R1 with mutagenesis, functional rescue, and mechanistic dissection of DISC formation","pmids":["30987996"],"is_preprint":false},{"year":2014,"finding":"Nuclear TRAIL-R2 (nTRAIL-R2) originates from the plasma membrane via TRAIL-dependent clathrin-mediated endocytosis. nTRAIL-R2 interacts with the nucleo-cytoplasmic shuttle protein Exportin-1/CRM-1; mutation of a putative nuclear export sequence (NES) in TRAIL-R2 or inhibition of CRM-1 by Leptomycin-B causes nuclear accumulation of TRAIL-R2. Nuclear TRAIL-R2 inhibits processing of primary let-7 miRNA (pri-let-7) by interacting with accessory proteins of the Microprocessor complex, thereby decreasing mature let-7 and enhancing malignancy.","method":"Co-immunoprecipitation (nTRAIL-R2 with Microprocessor components), NES mutagenesis, Leptomycin-B CRM-1 inhibition, nuclear fractionation, let-7 miRNA processing assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — review/synthesis paper covering multiple studies; primary data from referenced works","pmids":["25165876"],"is_preprint":false},{"year":2019,"finding":"TRAIL induces nuclear translocation of TRAIL-R1 and TRAIL-R2 from the plasma membrane via clathrin-dependent endocytosis in a TRAIL-dependent manner. Nuclear trafficking is rapid and involves interaction of nTRAIL-R2 with Exportin-1/CRM-1. NES mutation in TRAIL-R2 or CRM-1 inhibition (Leptomycin-B) causes nuclear accumulation. TRAIL-R1 and TRAIL-R2 constitutively localize to chromatin, which is strongly enhanced by TRAIL treatment.","method":"Cell surface biotinylation and intracellular tracking, clathrin inhibition, co-immunoprecipitation (TRAIL-R2/Exportin-1), NES mutagenesis, Leptomycin-B treatment, chromatin fractionation, immunofluorescence","journal":"Cancers","confidence":"High","confidence_rationale":"Tier 2 — surface biotinylation tracking plus genetic and pharmacological tools establishing nuclear trafficking mechanism","pmids":["31416165"],"is_preprint":false},{"year":2021,"finding":"A subset of LAMP1+TRAIL+ astrocytes limits CNS inflammation by inducing T cell apoptosis through TRAIL-DR5 signaling. In homeostatic conditions, TRAIL expression in astrocytes is driven by IFNγ produced by meningeal NK cells, which is modulated by the gut microbiome. T cells and microglia repress TRAIL expression in astrocytes during inflammation. CRISPR-Cas9-based in vivo genetic perturbations confirmed the role of astrocytic TRAIL in T cell killing.","method":"High-throughput flow cytometry screening, single-cell RNA sequencing, CRISPR-Cas9 in vivo genetic perturbations, T cell apoptosis assays (TRAIL-DR5 blocking), germ-free mouse models","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — CRISPR-Cas9 in vivo perturbation with multiple orthogonal methods; published in Nature","pmids":["33408417"],"is_preprint":false},{"year":2003,"finding":"In intestinal epithelial cells, TRAIL promotes differentiation rather than apoptosis despite expression of TRAIL-R1 and TRAIL-R2. TRAIL increases expression of cyclin-dependent kinase inhibitors p21 and p27 and the differentiation marker DPPIV. The differentiation-inducing activity was abolished by pre-incubation with Fc-TRAIL-R2 chimera, establishing TRAIL-R2 as the functional receptor mediating this non-apoptotic effect.","method":"Flow cytometry (receptor expression), recombinant TRAIL treatment, Fc-TRAIL-R2 chimera blocking, cell cycle analysis (p21/p27/DPPIV expression), differentiation assays","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 — receptor-blocking experiment plus differentiation marker analysis; single lab","pmids":["16245299"],"is_preprint":false},{"year":2004,"finding":"Megakaryocytes synthesize TRAIL during differentiation via increased transcriptional activity of the TRAIL promoter, and activated platelets express both membrane-bound and soluble TRAIL. Lineage-specific upregulation of TRAIL expression during megakaryocyte differentiation is mediated at the transcriptional level.","method":"Immunoprecipitation, ELISA, flow cytometry, RT-PCR, TRAIL promoter/reporter transient transfection, in vitro megakaryocyte differentiation","journal":"Experimental hematology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple methods establishing lineage-specific transcriptional regulation; single lab","pmids":["15539085"],"is_preprint":false},{"year":2021,"finding":"miR-24-3p from M2 macrophage-derived exosomes targets and inhibits Tnfsf10 (TRAIL) mRNA in cardiomyocytes. A direct binding relationship between miR-24-3p and the Tnfsf10 3'UTR was demonstrated. In a septic mouse model, Tnfsf10 expression is elevated in myocardial tissue; exosomal miR-24-3p or Tnfsf10 siRNA knockdown improved cardiac function and reduced cardiomyocyte apoptosis.","method":"Luciferase reporter assay (miR-24-3p binding to Tnfsf10 3'UTR), exosome isolation and miR-24-3p modification, Tnfsf10 siRNA knockdown, LPS-induced sepsis mouse model, cardiac function assays","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 — direct 3'UTR binding assay plus in vivo model; single lab","pmids":["34933177"],"is_preprint":false},{"year":2014,"finding":"Neutralization of TNFSF10 (TRAIL) by a monoclonal antibody in the 3xTg-AD Alzheimer's disease mouse model attenuates amyloid-β-induced neurotoxicity, improves cognitive function (Morris water maze, novel object recognition), and reduces expression of TNFSF10, amyloid-β, inflammatory mediators, and GFAP in the hippocampus. This establishes TNFSF10 as a mediator of amyloid-β neurotoxicity.","method":"Neutralizing monoclonal antibody administration, transgenic mouse model (3xTg-AD), Morris water maze and novel object recognition behavioral tests, protein expression analysis (TNFSF10, Aβ, GFAP, inflammatory mediators)","journal":"Brain","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo neutralization with behavioral and biochemical readouts; single lab","pmids":["25472798"],"is_preprint":false},{"year":2002,"finding":"TRAIL-mediated apoptosis of hepatocytes in vivo is triggered through TRAIL receptor DR5 and requires viral infection; uninfected hepatocytes in vivo are resistant to TRAIL-mediated apoptosis. Overexpression of TRAIL in the liver after viral infection is independent of lymphocytes, NK cells, and Kupffer cells, indicating a paracrine hepatocyte-autonomous mechanism against virally infected cells.","method":"Adenoviral hepatitis mouse model, DR5 blocking/knockout studies, liver histology, NK/lymphocyte depletion experiments, in vitro vs. in vivo TRAIL sensitivity comparison","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo mouse model with cell depletion experiments; mechanistic insight into tissue-specific TRAIL resistance","pmids":["12475902"],"is_preprint":false},{"year":2007,"finding":"Dengue virus (DV) induces TRAIL expression in immune cells and endothelial cells via an intact type I interferon signaling pathway. TRAIL functions as an antiviral protein: anti-TRAIL antibody treatment increased DV RNA accumulation, while recombinant TRAIL inhibited DV titers in dendritic cells by an apoptosis-independent mechanism.","method":"Affymetrix GeneChip microarray, anti-TRAIL antibody treatment, recombinant TRAIL treatment, DV RNA quantification and titer measurement, interferon pathway blockade","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 — antibody blocking and recombinant protein rescue experiments; apoptosis-independence established","pmids":["17913827"],"is_preprint":false},{"year":2002,"finding":"NF-κB transcription factors are key regulators of TRAIL expression in lymphocytes. TRAIL transcription is activated through an interferon-response element in its promoter. Decoy receptors TRAIL-R3/DcR1 and TRAIL-R4/DcR2 lack functional death domains and do not mediate apoptosis, providing a regulatory mechanism for differential sensitivity.","method":"NF-κB reporter assays, promoter analysis with interferon-response element, TRAIL receptor expression studies","journal":"Cytokine & growth factor reviews","confidence":"Low","confidence_rationale":"Tier 3 — review article summarizing mechanistic findings from other studies; no new primary data","pmids":["12486874"],"is_preprint":false}],"current_model":"TNFSF10 (TRAIL/Apo2L) is a homotrimeric type II transmembrane cytokine that induces apoptosis by binding two death-domain-containing receptors (TRAIL-R1/DR4 and TRAIL-R2/DR5), which recruit FADD and caspase-8 (and caspase-10 in a FADD-dependent but non-redundant manner) into a death-inducing signaling complex (DISC); full caspase-8 activation requires CUL3-mediated polyubiquitination and p62-dependent aggregation, and is further regulated by post-translational modifications including O-GlcNAcylation of DR4-Ser424 and O-glycosylation of DR4/DR5 ectodomains (which promote receptor clustering); three decoy/non-apoptotic receptors (TRAIL-R3, TRAIL-R4, and OPG) modulate signaling, while intracellular regulators including FLIP, IAPs, TRAF2, and DAPK2 control pathway output; TRAIL can also signal non-apoptotically via ERK (in erythroid differentiation), TAK1-AMPK (cytoprotective autophagy), NF-κB, and TRAIL-R2 nuclear trafficking to inhibit let-7 miRNA maturation; TRAIL gene expression is transcriptionally regulated by FOXO forkhead factors (via the PI3K-PTEN-Akt axis), NF-κB, interferon-response elements, Sp1 (under HDAC inhibitor treatment), and HDAC inhibitors acting directly on the TNFSF10 promoter."},"narrative":{"teleology":[{"year":1995,"claim":"Identification of TRAIL as a TNF-family cytokine that induces apoptosis in transformed cells answered the question of whether the TNF superfamily contained additional death ligands with tumor-selective activity.","evidence":"cDNA cloning and recombinant soluble protein apoptosis assays across diverse tumor lines","pmids":["8777713","8663110"],"confidence":"High","gaps":["Cognate receptor(s) unknown","Mechanism of tumor selectivity unexplained","In vivo physiological role not yet addressed"]},{"year":1997,"claim":"Rapid identification of four TRAIL receptors (DR4, DR5 with death domains; TRAIL-R3 and TRAIL-R4 as decoy/modulatory receptors) established a combinatorial receptor system governing differential cell sensitivity to TRAIL.","evidence":"Receptor cloning, binding affinity measurements, death domain functional assays, ectopic expression protection experiments, NF-κB reporter assays across multiple independent laboratories","pmids":["9082980","9311998","9242610","9373179","9430226","9325248","9314565"],"confidence":"High","gaps":["Proximal signaling adaptors at the DISC not yet defined for TRAIL receptors","Relative contributions of DR4 vs DR5 in different tissues unknown","Whether DR4 uses FADD was disputed across early studies"]},{"year":1997,"claim":"Demonstration that FADD, TRADD, and FLIP regulate TRAIL receptor signaling, and that DR4 and DR5 can form heterocomplexes, established the proximal adaptor framework for TRAIL-induced death signaling.","evidence":"Co-immunoprecipitation of FADD/TRADD with TRAIL receptors, dominant-negative FADD and FLIP overexpression blocking apoptosis","pmids":["9430228"],"confidence":"High","gaps":["Whether caspase-8 is recruited directly to the native DISC not yet shown","Stoichiometry of DISC components undefined"]},{"year":1999,"claim":"The crystal structure of the TRAIL trimer–DR5 ectodomain complex revealed the molecular basis of ligand–receptor interaction, showing three DR5 molecules bound in crevices between TRAIL monomers.","evidence":"X-ray crystallography of Apo2L/TRAIL–DR5 complex","pmids":["10549288"],"confidence":"High","gaps":["No structure of full-length receptor or intracellular DISC assembly","Structural basis for decoy receptor competition not resolved"]},{"year":2000,"claim":"Native DISC immunoprecipitation combined with FADD- and caspase-8-deficient cells proved that both FADD and caspase-8 are essential and independently recruited components of the TRAIL DISC, resolving earlier conflicting data.","evidence":"Native DISC precipitation from ligand-stimulated cells; FADD-deficient and caspase-8-deficient Jurkat genetic knockouts","pmids":["10894160"],"confidence":"High","gaps":["Post-translational regulation of caspase-8 at the DISC unknown","Role of caspase-10 not yet clarified"]},{"year":2002,"claim":"Multiple discoveries established transcriptional control of TRAIL: FOXO factors bind the TRAIL promoter (linking PI3K–PTEN–Akt to TRAIL expression), NF-κB and interferon-response elements also regulate transcription, and caspase-10 was shown to be recruited to the DISC in a FADD-dependent but caspase-8-non-redundant manner.","evidence":"Promoter reporter mapping (FKHRL1-responsive element at −138 to −121), adenoviral FOXO overexpression, caspase-10 native DISC immunoprecipitation and overexpression rescue in caspase-8-null cells","pmids":["12351634","12198154"],"confidence":"High","gaps":["Additional transcription factors and chromatin regulators not yet identified","Physiological role of caspase-10 in TRAIL signaling unclear"]},{"year":2003,"claim":"TRAIL was found to have non-apoptotic functions: ERK-dependent regulation of erythroid differentiation via TRAIL-R2, and differentiation induction (not apoptosis) in intestinal epithelial cells, expanding TRAIL biology beyond cell death.","evidence":"Pharmacological ERK/p38/JNK inhibitors in primary CD34+ erythroid cells; Fc-TRAIL-R2 chimera blocking in intestinal epithelial cells","pmids":["12969966","16245299"],"confidence":"High","gaps":["Downstream transcriptional targets of ERK in erythroid TRAIL signaling unknown","Mechanism linking TRAIL-R2 to p21/p27 induction in gut epithelium not defined"]},{"year":2004,"claim":"HDAC inhibitors were shown to directly activate the TNFSF10 promoter in AML cells, and FLIP was confirmed as a potent DISC-level inhibitor of caspase-8 activation, establishing two pharmacologically actionable nodes in the pathway.","evidence":"Promoter reporter assays with HDAC inhibitors, RNAi dissection of TRAIL/p21/differentiation, FLIP overexpression and knockdown with caspase-8 processing readouts","pmids":["15619633","15110178"],"confidence":"High","gaps":["Identity of the HDAC(s) that repress TRAIL transcription unknown","Whether FLIP regulation differs between TRAIL-R1 and TRAIL-R2 DISCs not addressed"]},{"year":2007,"claim":"O-glycosylation of DR4/DR5 ectodomains by GALNT14 was identified as a determinant of TRAIL sensitivity, promoting ligand-induced receptor clustering and caspase-8 activation—answering why cells with equivalent receptor levels differ in TRAIL responsiveness.","evidence":"GALNT14 RNAi/overexpression, mass spectrometry glycan mapping of DR5, progressive mutagenesis of O-glycosylation sites, receptor clustering assays","pmids":["17167167"],"confidence":"High","gaps":["Full set of glycosyltransferases modifying DR4/DR5 not catalogued","Structural mechanism by which O-glycans promote clustering unknown"]},{"year":2009,"claim":"Two key post-translational mechanisms were uncovered: CUL3-mediated polyubiquitination of caspase-8 (reversed by A20, read by p62) drives caspase-8 aggregation for full activation; and TRAIL-induced TAK1–AMPK signaling triggers cytoprotective autophagy in normal cells, explaining their TRAIL resistance.","evidence":"CUL3/RBX1/A20/p62 RNAi with DISC IP and caspase processing assays; TAK1/LKB1/CaMKKβ RNAi with AMPK/mTORC1 epistasis in normal vs. transformed cells","pmids":["19427028","19197243"],"confidence":"High","gaps":["Specific CUL3 substrate adaptor for caspase-8 not identified","Whether p62-mediated aggregation occurs in all TRAIL-sensitive cell types unknown","How TAK1 is activated by TRAIL receptors not mechanistically resolved"]},{"year":2014,"claim":"TRAF2 was established as a negative regulator of both TRAIL-induced apoptosis and necroptosis, and nuclear TRAIL-R2 was shown to inhibit let-7 miRNA maturation via the Microprocessor complex, revealing a non-canonical nuclear signaling function.","evidence":"TRAF2 siRNA with RIP3 reconstitution and necrostatin-1; TRAIL-R2 NES mutagenesis, CRM-1 inhibition, co-IP with Microprocessor components, let-7 processing assays","pmids":["25299769","25165876"],"confidence":"High","gaps":["Mechanism of TRAF2 recruitment to the TRAIL DISC not defined","Nuclear TRAIL-R2 findings based on limited cell types; generalizability unclear","Physiological significance of let-7 regulation by TRAIL-R2 in vivo not established"]},{"year":2019,"claim":"O-GlcNAcylation of DR4-Ser424 was identified as essential for DISC and necrosome formation, discriminating DR4 from DR5 signaling and linking metabolic status (glucose levels) to TRAIL sensitivity.","evidence":"OGT knockdown, DR4-S424 site-directed mutagenesis, DISC/necrosome co-IP, receptor clustering assays, cancer patient mutation screen, glucose modulation","pmids":["30987996"],"confidence":"High","gaps":["Whether other death domain residues are O-GlcNAcylated not surveyed","In vivo validation of glucose-dependent TRAIL sensitization lacking"]},{"year":2021,"claim":"TRAIL expression in LAMP1+ astrocytes, driven by IFNγ from meningeal NK cells and modulated by the gut microbiome, was shown to limit CNS inflammation by inducing T cell apoptosis—establishing a physiological immune-regulatory role for TRAIL in vivo.","evidence":"CRISPR-Cas9 in vivo perturbation of astrocytic TRAIL, scRNA-seq, germ-free mouse models, TRAIL-DR5 blocking","pmids":["33408417"],"confidence":"High","gaps":["Whether astrocytic TRAIL has non-apoptotic signaling effects on T cells unknown","Specific gut microbial taxa driving meningeal NK IFNγ not identified"]},{"year":null,"claim":"Key unresolved questions include the identity of the CUL3 substrate adaptor that ubiquitinates caspase-8, the structural basis of TRAIL-induced receptor clustering, the full spectrum of non-apoptotic TRAIL signaling outputs in different tissues, and the in vivo relevance of nuclear TRAIL-R2 in let-7 regulation.","evidence":"","pmids":[],"confidence":"High","gaps":["CUL3 substrate adaptor for caspase-8 ubiquitination unidentified","No full-length TRAIL receptor structure with intracellular domain","Tissue-specific balance between apoptotic and non-apoptotic TRAIL signaling not systematically mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,10,17]},{"term_id":"GO:0090729","term_label":"toxin activity","supporting_discovery_ids":[0,1,11]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1,34]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,34]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,1,11,12,21,29]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[32,37,38]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[6,7,22,24]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[20,26,27]}],"complexes":[],"partners":["TNFRSF10A","TNFRSF10B","TNFRSF10C","TNFRSF10D","FADD","CASP8","CFLAR","TRAF2"],"other_free_text":[]},"mechanistic_narrative":"TNFSF10 (TRAIL/Apo2L) is a homotrimeric type II transmembrane cytokine of the TNF superfamily that induces apoptosis in transformed cells by engaging the death-domain-containing receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2), which recruit FADD and caspase-8 into a death-inducing signaling complex (DISC); full caspase-8 activation requires CUL3-mediated polyubiquitination and p62-dependent aggregation, and is modulated by post-translational modifications including O-glycosylation of DR4/DR5 ectodomains (promoting receptor clustering) and O-GlcNAcylation of DR4-Ser424 [PMID:8777713, PMID:10894160, PMID:19427028, PMID:17167167, PMID:30987996]. Apoptotic signaling is negatively regulated by decoy receptors (TRAIL-R3, TRAIL-R4), the caspase-8 inhibitor FLIP, and TRAF2, while TRAIL-R4 additionally activates NF-κB [PMID:9242610, PMID:9430226, PMID:25299769]. Beyond apoptosis, TRAIL signals non-apoptotically through ERK to regulate erythroid differentiation, through TAK1–AMPK to induce cytoprotective autophagy in normal epithelial cells, and through nuclear TRAIL-R2 trafficking to inhibit let-7 miRNA maturation [PMID:12969966, PMID:19197243, PMID:31416165]. TRAIL gene expression is transcriptionally controlled by FOXO factors (via the PI3K–PTEN–Akt axis), NF-κB, interferon-response elements, and Sp1 (recruited upon HDAC inhibitor treatment), and is induced in astrocytes by IFNγ from meningeal NK cells to limit CNS inflammation via T cell apoptosis [PMID:12351634, PMID:15619633, PMID:18701496, PMID:33408417]."},"prefetch_data":{"uniprot":{"accession":"P50591","full_name":"Tumor necrosis factor ligand superfamily member 10","aliases":["Apo-2 ligand","Apo-2L","TNF-related apoptosis-inducing ligand","Protein TRAIL"],"length_aa":281,"mass_kda":32.5,"function":"Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG (PubMed:10549288, PubMed:26457518). Induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis","subcellular_location":"Cell membrane; Secreted","url":"https://www.uniprot.org/uniprotkb/P50591/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TNFSF10","classification":"Not Classified","n_dependent_lines":18,"n_total_lines":1208,"dependency_fraction":0.014900662251655629},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TNFSF10","total_profiled":1310},"omim":[{"mim_id":"617464","title":"UNC5 FAMILY C-TERMINAL-LIKE PROTEIN; UNC5CL","url":"https://www.omim.org/entry/617464"},{"mim_id":"617078","title":"DEATH EFFECTOR DOMAIN-CONTAINING PROTEIN 2; DEDD2","url":"https://www.omim.org/entry/617078"},{"mim_id":"616147","title":"CYCLIN-DEPENDENT KINASE 15; CDK15","url":"https://www.omim.org/entry/616147"},{"mim_id":"616068","title":"HOXA CLUSTER ANTISENSE RNA 2, NONCODING; HOXAAS2","url":"https://www.omim.org/entry/616068"},{"mim_id":"615741","title":"DAP3-BINDING CELL DEATH ENHANCER 1; DELE1","url":"https://www.omim.org/entry/615741"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TNFSF10"},"hgnc":{"alias_symbol":["TRAIL","Apo-2L","TL2","CD253","TANCR"],"prev_symbol":[]},"alphafold":{"accession":"P50591","domains":[{"cath_id":"2.60.120.40","chopping":"122-278","consensus_level":"high","plddt":89.5218,"start":122,"end":278},{"cath_id":"1.20.1070","chopping":"23-56_76-88","consensus_level":"medium","plddt":84.2866,"start":23,"end":88}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P50591","model_url":"https://alphafold.ebi.ac.uk/files/AF-P50591-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P50591-F1-predicted_aligned_error_v6.png","plddt_mean":81.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TNFSF10","jax_strain_url":"https://www.jax.org/strain/search?query=TNFSF10"},"sequence":{"accession":"P50591","fasta_url":"https://rest.uniprot.org/uniprotkb/P50591.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P50591/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P50591"}},"corpus_meta":[{"pmid":"9082980","id":"PMC_9082980","title":"The receptor for the cytotoxic ligand TRAIL.","date":"1997","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9082980","citation_count":1489,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9311998","id":"PMC_9311998","title":"TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.","date":"1997","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9311998","citation_count":967,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12655296","id":"PMC_12655296","title":"Apo2L/TRAIL and its death and decoy receptors.","date":"2003","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/12655296","citation_count":711,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15353805","id":"PMC_15353805","title":"A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death.","date":"2004","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/15353805","citation_count":562,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17403612","id":"PMC_17403612","title":"TRAIL signalling: decisions between life and death.","date":"2007","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/17403612","citation_count":377,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33408417","id":"PMC_33408417","title":"Gut-licensed IFNγ+ NK cells drive LAMP1+TRAIL+ anti-inflammatory astrocytes.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/33408417","citation_count":265,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9373179","id":"PMC_9373179","title":"Characterization of two receptors for TRAIL.","date":"1997","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9373179","citation_count":241,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29541897","id":"PMC_29541897","title":"Developing TRAIL/TRAIL death receptor-based cancer therapies.","date":"2018","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/29541897","citation_count":206,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12628743","id":"PMC_12628743","title":"TRAIL-induced signalling and apoptosis.","date":"2003","source":"Toxicology letters","url":"https://pubmed.ncbi.nlm.nih.gov/12628743","citation_count":192,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25883904","id":"PMC_25883904","title":"Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells.","date":"2015","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25883904","citation_count":183,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11905805","id":"PMC_11905805","title":"How melanoma cells evade trail-induced apoptosis.","date":"2001","source":"Nature reviews. Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11905805","citation_count":182,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19836385","id":"PMC_19836385","title":"TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.","date":"2009","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19836385","citation_count":155,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16884904","id":"PMC_16884904","title":"The clinical trail of TRAIL.","date":"2006","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/16884904","citation_count":148,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12517970","id":"PMC_12517970","title":"Acceleration of human neutrophil apoptosis by TRAIL.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12517970","citation_count":144,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9382834","id":"PMC_9382834","title":"Cell death: TRAIL and its receptors.","date":"1997","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/9382834","citation_count":140,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16357130","id":"PMC_16357130","title":"TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16357130","citation_count":137,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20819019","id":"PMC_20819019","title":"TRAIL receptor signaling and therapeutics.","date":"2010","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/20819019","citation_count":126,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11388668","id":"PMC_11388668","title":"The potential of TRAIL for cancer chemotherapy.","date":"2001","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/11388668","citation_count":124,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12969966","id":"PMC_12969966","title":"TRAIL regulates normal erythroid maturation through an ERK-dependent pathway.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12969966","citation_count":110,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12475902","id":"PMC_12475902","title":"Involvement of TRAIL and its receptors in viral hepatitis.","date":"2002","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/12475902","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18287563","id":"PMC_18287563","title":"The death ligand TRAIL in diabetic nephropathy.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/18287563","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18381408","id":"PMC_18381408","title":"Mcl-1: a gateway to TRAIL sensitization.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18381408","citation_count":98,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31561055","id":"PMC_31561055","title":"The TRAIL to cancer therapy: Hindrances and potential solutions.","date":"2019","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/31561055","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37345089","id":"PMC_37345089","title":"The Role of TRAIL in Apoptosis and Immunosurveillance in Cancer.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/37345089","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12486874","id":"PMC_12486874","title":"On the TRAIL to apoptosis.","date":"2002","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/12486874","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22892844","id":"PMC_22892844","title":"Regulation of the human TRAIL gene.","date":"2012","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/22892844","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10198234","id":"PMC_10198234","title":"Expression of TRAIL and its receptors in human brain tumors.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10198234","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30943823","id":"PMC_30943823","title":"Nutrition for Ultramarathon Running: Trail, Track, and Road.","date":"2019","source":"International journal of sport nutrition and exercise metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30943823","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25299769","id":"PMC_25299769","title":"TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis.","date":"2014","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/25299769","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25472798","id":"PMC_25472798","title":"Neutralization of TNFSF10 ameliorates functional outcome in a murine model of Alzheimer's disease.","date":"2014","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25472798","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21072058","id":"PMC_21072058","title":"Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level.","date":"2010","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/21072058","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24909167","id":"PMC_24909167","title":"TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24909167","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17613431","id":"PMC_17613431","title":"Clearing the TRAIL for Cancer Therapy.","date":"2007","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/17613431","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18061141","id":"PMC_18061141","title":"Expression, regulation and function of trail in atherosclerosis.","date":"2007","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18061141","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11991679","id":"PMC_11991679","title":"Potential and caveats of TRAIL in cancer therapy.","date":"2001","source":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/11991679","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27111415","id":"PMC_27111415","title":"Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL.","date":"2016","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/27111415","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10695081","id":"PMC_10695081","title":"The oxygen trail: tissue oxygenation.","date":"1999","source":"British medical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/10695081","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8290248","id":"PMC_8290248","title":"Interaction of hepatitis B virus X protein with a serine protease, tryptase TL2 as an inhibitor.","date":"1994","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8290248","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17913827","id":"PMC_17913827","title":"TRAIL is a novel antiviral protein against dengue virus.","date":"2007","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/17913827","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27740879","id":"PMC_27740879","title":"Hepatitis B virus-triggered autophagy targets TNFRSF10B/death receptor 5 for degradation to limit TNFSF10/TRAIL response.","date":"2016","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/27740879","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15110178","id":"PMC_15110178","title":"FLIP protein and TRAIL-induced apoptosis.","date":"2004","source":"Vitamins and hormones","url":"https://pubmed.ncbi.nlm.nih.gov/15110178","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15771956","id":"PMC_15771956","title":"Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5.","date":"2005","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/15771956","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25165876","id":"PMC_25165876","title":"Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2.","date":"2014","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/25165876","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17240413","id":"PMC_17240413","title":"TRAIL death receptors and cancer therapeutics.","date":"2006","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17240413","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31444476","id":"PMC_31444476","title":"TRAIL-based gene delivery and therapeutic strategies.","date":"2019","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/31444476","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25703843","id":"PMC_25703843","title":"On the organ trail: insights into organ regeneration in the planarian.","date":"2015","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/25703843","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25607248","id":"PMC_25607248","title":"Poly-ADP-ribosylation of HMGB1 regulates TNFSF10/TRAIL resistance through autophagy.","date":"2015","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/25607248","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23203129","id":"PMC_23203129","title":"Targeting death receptor TRAIL-R2 by chalcones for TRAIL-induced apoptosis in cancer cells.","date":"2012","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23203129","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17485268","id":"PMC_17485268","title":"The role of TRAIL/TRAIL receptors in central nervous system pathology.","date":"2007","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/17485268","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22407575","id":"PMC_22407575","title":"Resistance to TRAIL and how to surmount it.","date":"2012","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/22407575","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21220186","id":"PMC_21220186","title":"Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL.","date":"2011","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/21220186","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16224489","id":"PMC_16224489","title":"On the TRAIL of a new therapy for leukemia.","date":"2005","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/16224489","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12833134","id":"PMC_12833134","title":"Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect.","date":"2003","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/12833134","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20691980","id":"PMC_20691980","title":"Triptolide and TRAIL combination enhances apoptosis in cholangiocarcinoma.","date":"2010","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/20691980","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19247452","id":"PMC_19247452","title":"HIV induces TRAIL sensitivity in hepatocytes.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19247452","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17172650","id":"PMC_17172650","title":"Following the TRAIL to apoptosis.","date":"2006","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/17172650","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17786298","id":"PMC_17786298","title":"The NO TRAIL to YES TRAIL in cancer therapy (review).","date":"2007","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17786298","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16574768","id":"PMC_16574768","title":"On the production of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2L) by human neutrophils.","date":"2006","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/16574768","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31297857","id":"PMC_31297857","title":"Upregulation of long noncoding TNFSF10 contributes to osteoarthritis progression through the miR-376-3p/FGFR1 axis.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31297857","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18701496","id":"PMC_18701496","title":"Sp1-mediated TRAIL induction in chemosensitization.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18701496","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19540014","id":"PMC_19540014","title":"Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis.","date":"2009","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/19540014","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28914952","id":"PMC_28914952","title":"Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy.","date":"2017","source":"Nanoscale","url":"https://pubmed.ncbi.nlm.nih.gov/28914952","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16245299","id":"PMC_16245299","title":"Involvement of TRAIL/TRAIL-receptors in human intestinal cell differentiation.","date":"2006","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16245299","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33401962","id":"PMC_33401962","title":"Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy.","date":"2021","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/33401962","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10960444","id":"PMC_10960444","title":"Expression and antitumor effects of TRAIL in human cholangiocarcinoma.","date":"2000","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/10960444","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16922616","id":"PMC_16922616","title":"TRAIL receptor-targeted therapy.","date":"2006","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16922616","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34611142","id":"PMC_34611142","title":"Targeting the miRNA-155/TNFSF10 network restrains inflammatory response in the retina in a mouse model of Alzheimer's disease.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34611142","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25012503","id":"PMC_25012503","title":"DAPK2 is a novel modulator of TRAIL-induced apoptosis.","date":"2014","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/25012503","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15110188","id":"PMC_15110188","title":"Regulation of sensitivity to TRAIL by the PTEN tumor suppressor.","date":"2004","source":"Vitamins and hormones","url":"https://pubmed.ncbi.nlm.nih.gov/15110188","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36629496","id":"PMC_36629496","title":"Therapeutic targeting of TRAIL death receptors.","date":"2023","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/36629496","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12371944","id":"PMC_12371944","title":"A trail of research on potassium.","date":"2002","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/12371944","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32245106","id":"PMC_32245106","title":"On the TRAIL of Better Therapies: Understanding TNFRSF Structure-Function.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32245106","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7598488","id":"PMC_7598488","title":"A research trail over half a century.","date":"1995","source":"Annual review of pharmacology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/7598488","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15539085","id":"PMC_15539085","title":"Expression of TNF-related apoptosis-inducing ligand (TRAIL) in megakaryocytes and platelets.","date":"2004","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/15539085","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17127445","id":"PMC_17127445","title":"Apo2L/TRAIL and immune regulation.","date":"2007","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/17127445","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18469516","id":"PMC_18469516","title":"TRAIL death receptors as tumor suppressors and drug targets.","date":"2008","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/18469516","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33919846","id":"PMC_33919846","title":"Overcoming TRAIL Resistance for Glioblastoma Treatment.","date":"2021","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/33919846","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34933177","id":"PMC_34933177","title":"Cardioprotection of M2 macrophages-derived exosomal microRNA-24-3p/Tnfsf10 axis against myocardial injury after sepsis.","date":"2021","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34933177","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15110182","id":"PMC_15110182","title":"Modulation of TRAIL signaling for cancer therapy.","date":"2004","source":"Vitamins and hormones","url":"https://pubmed.ncbi.nlm.nih.gov/15110182","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20068388","id":"PMC_20068388","title":"Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism.","date":"2009","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/20068388","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30740527","id":"PMC_30740527","title":"TRAIL pathway targeting therapeutics.","date":"2018","source":"Expert review of precision medicine and drug development","url":"https://pubmed.ncbi.nlm.nih.gov/30740527","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27528614","id":"PMC_27528614","title":"Differences and Similarities in TRAIL- and Tumor Necrosis Factor-Mediated Necroptotic Signaling in Cancer Cells.","date":"2016","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27528614","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27989503","id":"PMC_27989503","title":"A Purinergic Trail for Metastases.","date":"2016","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27989503","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30101145","id":"PMC_30101145","title":"Divergent Roles for TRAIL in Lung Diseases.","date":"2018","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30101145","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19077262","id":"PMC_19077262","title":"TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma.","date":"2008","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/19077262","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27029345","id":"PMC_27029345","title":"Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme.","date":"2016","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/27029345","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25647515","id":"PMC_25647515","title":"Novel TRAIL sensitizer Taraxacum officinale F.H. Wigg enhances TRAIL-induced apoptosis in Huh7 cells.","date":"2015","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/25647515","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26735596","id":"PMC_26735596","title":"Nucleic Acid Engineering: RNA Following the Trail of DNA.","date":"2016","source":"ACS combinatorial science","url":"https://pubmed.ncbi.nlm.nih.gov/26735596","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22589394","id":"PMC_22589394","title":"Resistance to TRAIL is mediated by DARPP-32 in gastric cancer.","date":"2012","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/22589394","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33731677","id":"PMC_33731677","title":"Splicing reprogramming of TRAIL/DISC-components sensitizes lung cancer cells to TRAIL-mediated apoptosis.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33731677","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21762072","id":"PMC_21762072","title":"Therapeutic targeting of CD95 and the TRAIL death receptors.","date":"2011","source":"Recent patents on anti-cancer drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/21762072","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31078569","id":"PMC_31078569","title":"Co-delivery of TRAIL and siHSP70 using hierarchically modular assembly formulations achieves enhanced TRAIL-resistant cancer therapy.","date":"2019","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/31078569","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26381901","id":"PMC_26381901","title":"Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.","date":"2015","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/26381901","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39106819","id":"PMC_39106819","title":"Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer.","date":"2024","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/39106819","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15110170","id":"PMC_15110170","title":"Promoter of TRAIL-R2 gene.","date":"2004","source":"Vitamins and hormones","url":"https://pubmed.ncbi.nlm.nih.gov/15110170","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6220515","id":"PMC_6220515","title":"The tL2 cluster of transcription termination sites between genes bet and ral of coliphage lambda.","date":"1983","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/6220515","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30987996","id":"PMC_30987996","title":"DR4-Ser424 O-GlcNAcylation Promotes Sensitization of TRAIL-Tolerant Persisters and TRAIL-Resistant Cancer Cells to Death.","date":"2019","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30987996","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19823030","id":"PMC_19823030","title":"The Par-4-GRP78 TRAIL, more twists and turns.","date":"2009","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/19823030","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18223207","id":"PMC_18223207","title":"Role of IG20 splice variants in TRAIL resistance.","date":"2008","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/18223207","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31416165","id":"PMC_31416165","title":"TRAIL Induces Nuclear Translocation and Chromatin Localization of TRAIL Death Receptors.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31416165","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9520411","id":"PMC_9520411","title":"Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9520411","citation_count":3272,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8777713","id":"PMC_8777713","title":"Identification and characterization of a new member of the TNF family that induces apoptosis.","date":"1995","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/8777713","citation_count":2449,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16169070","id":"PMC_16169070","title":"A human protein-protein interaction network: a resource for annotating the proteome.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16169070","citation_count":1704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8663110","id":"PMC_8663110","title":"Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8663110","citation_count":1549,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9242610","id":"PMC_9242610","title":"An antagonist decoy receptor and a death domain-containing receptor for TRAIL.","date":"1997","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9242610","citation_count":1312,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14644197","id":"PMC_14644197","title":"Mechanisms of caspase activation.","date":"2003","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/14644197","citation_count":1028,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9430226","id":"PMC_9430226","title":"The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain.","date":"1997","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9430226","citation_count":700,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10894160","id":"PMC_10894160","title":"FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2.","date":"2000","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/10894160","citation_count":683,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12118245","id":"PMC_12118245","title":"Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.","date":"2002","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12118245","citation_count":623,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9430228","id":"PMC_9430228","title":"TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB.","date":"1997","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9430228","citation_count":598,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9314565","id":"PMC_9314565","title":"Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family.","date":"1997","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9314565","citation_count":529,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19427028","id":"PMC_19427028","title":"Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19427028","citation_count":511,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17767167","id":"PMC_17767167","title":"Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.","date":"2007","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17767167","citation_count":480,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9325248","id":"PMC_9325248","title":"Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9325248","citation_count":478,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12787570","id":"PMC_12787570","title":"Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy.","date":"2003","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/12787570","citation_count":471,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15619633","id":"PMC_15619633","title":"Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells.","date":"2004","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15619633","citation_count":452,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26098775","id":"PMC_26098775","title":"Citrus limon-derived nanovesicles inhibit cancer cell proliferation and suppress CML xenograft growth by inducing TRAIL-mediated cell death.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26098775","citation_count":393,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10549288","id":"PMC_10549288","title":"Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5.","date":"1999","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/10549288","citation_count":378,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18640940","id":"PMC_18640940","title":"Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).","date":"2008","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18640940","citation_count":347,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19197243","id":"PMC_19197243","title":"TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells.","date":"2009","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/19197243","citation_count":337,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12761501","id":"PMC_12761501","title":"Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12761501","citation_count":331,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19435900","id":"PMC_19435900","title":"Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19435900","citation_count":325,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12351634","id":"PMC_12351634","title":"FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12351634","citation_count":314,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12198154","id":"PMC_12198154","title":"Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12198154","citation_count":280,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11940602","id":"PMC_11940602","title":"An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11940602","citation_count":273,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":42836,"output_tokens":5954,"usd":0.108909},"stage2":{"model":"claude-opus-4-6","input_tokens":9557,"output_tokens":3604,"usd":0.206827},"total_usd":0.737869,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":55207,"output_tokens":11203,"usd":0.166833},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":15045,"output_tokens":3799,"usd":0.2553}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"TRAIL (TNFSF10) binds and activates DR4 (TRAIL-R1), a TNF receptor family member containing a cytoplasmic death domain, to induce apoptosis; DR4 could not use FADD to transmit the death signal, suggesting distinct proximal signaling machinery compared to Fas/TNFR-1/DR3.\",\n      \"method\": \"Receptor identification by homology searching, functional overexpression, death domain interaction assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — foundational receptor identification paper, >1400 citations, replicated across the field\",\n      \"pmids\": [\"9082980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TRAIL (TNFSF10) binds a second distinct receptor, TRAIL-R2 (DR5), purified by ligand-based affinity purification from human cell lines; TRAIL-R2 contains two extracellular cysteine-rich repeats and a cytoplasmic death domain, mediates caspase-dependent apoptosis via the intracellular adaptor FADD/MORT1, and a TRAIL-R2-Fc fusion protein inhibits TRAIL-induced apoptosis.\",\n      \"method\": \"Ligand-based affinity purification, molecular cloning, TRAIL-R2-Fc fusion protein blocking assay, FADD interaction assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — affinity purification, functional blocking, FADD interaction, >960 citations\",\n      \"pmids\": [\"9311998\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TRAIL (TNFSF10) binds TRAIL-R3, a non-apoptotic decoy receptor that is highly glycosylated, membrane-bound via a putative phosphatidylinositol anchor, and contains TAPE repeats; all three receptors bind TRAIL with similar affinity, suggesting complex regulation of TRAIL-mediated signals.\",\n      \"method\": \"Receptor characterization, binding affinity assays, structural analysis\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct receptor characterization with binding affinity measurements, >240 citations\",\n      \"pmids\": [\"9373179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TRAIL (TNFSF10) induces apoptosis through formation of a death-inducing signalling complex (DISC) at TRAIL-R1 and TRAIL-R2; this DISC recruits and activates a caspase cascade; TRAIL also activates NF-κB and interacts with the intrinsic (Bcl-2-regulated mitochondrial) pathway in determining cell fate.\",\n      \"method\": \"DISC biochemical characterization, caspase activation assays, NF-κB reporter assays, review of mechanistic studies\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — synthesis of multiple mechanistic studies from multiple labs, >710 citations\",\n      \"pmids\": [\"12655296\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"TRAIL (TNFSF10)-induced apoptosis is potentiated by a small molecule Smac mimic that binds XIAP, cIAP-1, and cIAP-2, relieving IAP-mediated suppression of caspase activity downstream of TRAIL receptor signaling; this allowed temporal evaluation showing IAPs function during TRAIL receptor signaling.\",\n      \"method\": \"In vitro binding assays, caspase activation assays, apoptosis assays in human cancer cells\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro binding plus functional caspase assays, replicated in multiple cell lines\",\n      \"pmids\": [\"15353805\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TRAIL (TNFSF10) receptor-selective mutants signal apoptosis in primary chronic lymphocytic leukemia (CLL) and mantle cell lymphoma cells almost exclusively through TRAIL-R1 (DR4), not TRAIL-R2 (DR5); selectivity is due to receptor-specific binding resulting in DISC formation.\",\n      \"method\": \"Synthesis of TRAIL-R1- and TRAIL-R2-selective TRAIL mutants, DISC formation assays, apoptosis assays in primary patient cells\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor-selective mutants with DISC formation assays in primary patient samples\",\n      \"pmids\": [\"16357130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TRAIL-R4 expressed on cancer cells inhibits TRAIL-induced apoptosis by acting at the DISC level; chemotherapy restores TRAIL sensitivity in TRAIL-R4-expressing cells through enhanced caspase-8 recruitment and activation at the DISC, independently of mitochondria; c-FLIP cooperates with TRAIL-R4 to inhibit TRAIL-induced cell death.\",\n      \"method\": \"Ectopic and endogenous TRAIL-R4 expression, DISC analysis, caspase-8 recruitment assays, tumor xenograft experiments\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — DISC biochemical analysis, in vivo xenograft validation, multiple cell models\",\n      \"pmids\": [\"21072058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TRAF2 acts as a negative regulator of TRAIL (TNFSF10)-induced apoptosis and necroptosis; TRAF2 knockdown sensitizes cells to TRAIL-induced caspase-dependent apoptosis and, in RIP3-expressing cells, also to TRAIL-induced necroptosis mediated through RIP1; TRAIL-induced necroptosis is independent of autocrine TNF/TNFR signaling.\",\n      \"method\": \"siRNA knockdown of TRAF2, pan-caspase inhibitor zVAD-fmk, necrostatin-1 (RIP1 inhibitor), stable RIP3-expressing HeLa cells, blocking antibodies to TNF\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal inhibitors, genetic knockdown, RIP3-expressing cell model with appropriate controls\",\n      \"pmids\": [\"25299769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TRAIL-R2 (TNFRSF10B) is present in the nucleus of tumor cells and inhibits processing of primary let-7 miRNA (pri-let-7) via interaction with accessory proteins of the Microprocessor complex; nuclear TRAIL-R2 originates from the plasma membrane via clathrin-dependent endocytosis and its nuclear trafficking is TRAIL-dependent; nuclear export involves Exportin-1/CRM-1 via a nuclear export sequence in TRAIL-R2.\",\n      \"method\": \"Cell surface biotinylation, protein tracking in intracellular compartments, immunoprecipitation, immunofluorescence, CRM-1 inhibition, NES mutagenesis\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including biotinylation tracking, mutagenesis, pharmacological inhibition\",\n      \"pmids\": [\"25165876\", \"31416165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DR4/TRAIL-R1 (the receptor for TRAIL/TNFSF10) is O-GlcNAcylated at Ser424 within its death domain; this modification is required for DISC/necrosome formation, receptor clustering in aggregated platforms, and for both apoptotic and necroptotic cell death upon TRAIL ligation; DR5 is not O-GlcNAcylated by TRAIL treatment; promoting DR4 O-GlcNAcylation with 2-deoxy-d-glucose sensitizes TRAIL-resistant cells.\",\n      \"method\": \"O-GlcNAc transferase knockdown, cancer patient-derived cDNA screen, Ser424 mutagenesis, DISC/necrosome formation assays, DR5-neutralizing antibody, glucose modulation experiments\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — site-specific mutagenesis, OGT knockdown, multiple cell models, DISC formation assays\",\n      \"pmids\": [\"30987996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Hepatitis B virus X protein (HBx) restricts TRAIL (TNFSF10) receptor signaling by promoting autophagy-mediated lysosomal degradation of TRAIL-R2/DR5; HBx directly interacts with TRAIL-R2 and recruits it to phagophores via an autophagy receptor-like mechanism involving LC3B; inhibition of autophagy enhances hepatocyte susceptibility to TRAIL.\",\n      \"method\": \"Immunoblotting for LC3B/SQSTM1, tandem-fluorescence LC3B microscopy, immunoprecipitation, GST affinity isolation, LC3B knockdown, pharmacological autophagy inhibition\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — direct interaction by Co-IP and GST pulldown, LC3B knockdown, imaging of autophagosome recruitment\",\n      \"pmids\": [\"27740879\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TRAIL (TNFSF10) regulates human erythroid maturation through ERK1/2 signaling; TRAIL inhibits generation of morphologically mature erythroblasts in an ERK-dependent manner (blocked by PD98059) independent of caspase activation (not blocked by z-VAD-fmk); TRAIL-R2 is expressed throughout erythroid differentiation while TRAIL-R1 is weakly expressed early.\",\n      \"method\": \"Serum-free liquid phase differentiation of CD34+ cord blood progenitors, ERK1/2 phosphorylation assays, pharmacological inhibitors (PD98059, z-VAD-fmk, SB203580), flow cytometry\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined ERK-dependent pathway by pharmacological inhibition in a primary cell differentiation model\",\n      \"pmids\": [\"12969966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TRAIL (TNFSF10) accelerates apoptosis of human neutrophils via TRAIL-R2; neutrophils express TRAIL, TRAIL-R2, and TRAIL-R3 mRNA and cell surface protein; blocking TRAIL-R2 with specific antibodies or TRAIL-R1-Fc fusion protein abrogates the proapoptotic effect; TRAIL does not activate NF-κB in neutrophils.\",\n      \"method\": \"Blocking antibodies to TRAIL-R2, TRAIL-R1:FcR fusion protein, NF-κB inhibitor gliotoxin, leucine zipper-tagged TRAIL, flow cytometry, apoptosis assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor-specific blocking antibodies with functional readout, multiple controls, primary human cells\",\n      \"pmids\": [\"12517970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TRAIL (TNFSF10) expression in immune cells is regulated by NF-κB transcription factors; TRAIL is constitutively expressed in many human tissues and its expression in cancer immunosurveillance is driven by interferon-response elements in the TRAIL gene promoter.\",\n      \"method\": \"NF-κB reporter assays, promoter analysis\",\n      \"journal\": \"Cytokine & growth factor reviews\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — functional promoter studies described in review context; individual studies cited\",\n      \"pmids\": [\"12486874\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Transcription factor Sp1 mediates TRAIL (TNFSF10) gene induction by HDAC inhibitor MS275 alone or in combination with Adriamycin in breast cancer cells; Sp1 knockdown and Sp1-knockout cells are resistant to this induction; TRAIL induction mediates apoptosis via both death receptor and mitochondrial pathways.\",\n      \"method\": \"Reporter constructs, chromatin immunoprecipitation, Sp1 siRNA knockdown, Sp1-knockout mouse embryonic stem cells\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP, genetic knockout validation, siRNA, multiple orthogonal methods\",\n      \"pmids\": [\"18701496\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LAMP1+TRAIL+ astrocytes in the CNS limit inflammation by inducing T cell apoptosis through TRAIL-DR5 signaling; astrocyte TRAIL expression is driven by IFNγ produced by meningeal NK cells (licensed by gut microbiome) and is repressed by T cell- and microglia-derived signals during inflammation.\",\n      \"method\": \"High-throughput flow cytometry screening, single-cell RNA sequencing, CRISPR-Cas9 cell-specific in vivo genetic perturbations in mice\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR-Cas9 in vivo perturbation, scRNA-seq, flow cytometry in mouse model\",\n      \"pmids\": [\"33408417\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"TRAIL (TNFSF10) expressed by platelets and megakaryocytes includes both membrane-bound and soluble forms; TRAIL expression is induced upon megakaryocyte differentiation and is mediated by increased transcriptional activity of the TRAIL promoter, indicating lineage-specific regulation.\",\n      \"method\": \"Immunoprecipitation, ELISA, flow cytometry, RT-PCR, transient transfection of TRAIL promoter/reporter constructs, TRAIL-dependent cytotoxicity assays\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter/reporter assays, multiple protein detection methods, functional cytotoxicity assay\",\n      \"pmids\": [\"15539085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PARP1-mediated poly-ADP-ribosylation of HMGB1 is required for TRAIL (TNFSF10)-induced HMGB1 cytoplasmic translocation and subsequent HMGB1-BECN1 complex formation, which drives autophagy; suppression of the PARP1-HMGB1 pathway diminishes autophagy, increases apoptosis, and enhances TRAIL anticancer activity in vitro and in vivo.\",\n      \"method\": \"PARP1 inhibitors, PARP1 knockdown, HMGB1 translocation assays, co-immunoprecipitation (HMGB1-BECN1), subcutaneous tumor model\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and genetic manipulation with complex formation assay and in vivo validation\",\n      \"pmids\": [\"25607248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"DAPK2 (death-associated protein kinase 2) modulates TRAIL (TNFSF10) signaling; DAPK2 knockdown causes NF-κB phosphorylation and transcriptional activation, leading to upregulation of DR4 and DR5 on the cell surface and sensitization of resistant cancer cells to TRAIL-induced killing in a p53-independent manner.\",\n      \"method\": \"RNA interference, NF-κB reporter assays, cell surface receptor expression by flow cytometry, apoptosis assays in multiple cancer cell lines\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockdown with defined pathway placement (DAPK2→NF-κB→DR4/DR5) in multiple cell lines\",\n      \"pmids\": [\"25012503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TRAIL (TNFSF10) mediates necroptosis through mechanisms including acid and neutral sphingomyelinases, mitochondrial serine protease HtrA2/Omi, Atg5, and vacuolar H+-ATPase; TRAIL-mediated necroptosis is independent of PARP-1, does not require receptor internalization or endosome-lysosome acidification, and differs from TNF-mediated necroptosis in not requiring UCH-L1 or Atg16L1; Bcl-XL overexpression diminishes specifically TRAIL-induced necroptosis.\",\n      \"method\": \"Genetic knockdown/overexpression, pharmacological inhibitors, RIP3-overexpressing cells, apoptosis/necroptosis discrimination assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacological approaches distinguishing TRAIL necroptosis pathway components\",\n      \"pmids\": [\"27528614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"AMG655 (TRAIL-R2-specific antibody) and non-tagged TRAIL (Apo2L/TRAIL) synergize to kill cancer cells through enhanced formation of the TRAIL death-inducing signalling complex (DISC), enabled by concomitant binding of both agents to TRAIL-R2; this combination does not kill primary human hepatocytes.\",\n      \"method\": \"DISC formation assays, Co-IP, apoptosis assays in cancer cell lines and primary ovarian cancer cells, hepatocyte toxicity assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct DISC formation assay mechanistically explaining synergy, validated in primary cells\",\n      \"pmids\": [\"24909167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TRAIL (TNFSF10) is a novel antiviral protein against dengue virus; TRAIL induction by dengue virus is dependent on an intact type I interferon signaling pathway; recombinant TRAIL inhibits DV titers in dendritic cells by an apoptosis-independent mechanism; TRAIL expression is induced in immune cells and HUVECs at mRNA and protein levels upon DV infection.\",\n      \"method\": \"Anti-TRAIL antibody treatment, recombinant TRAIL treatment, quantification of DV RNA, Affymetrix GeneChip expression profiling, type I IFN pathway knockout analysis\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — antibody blocking and recombinant protein rescue experiments with direct viral RNA quantification\",\n      \"pmids\": [\"17913827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TRAIL (TNFSF10) acts as a paracrine trophic cytokine on intestinal epithelium promoting cell differentiation; TRAIL increases expression of cyclin-dependent kinase inhibitors p21 and p27 and differentiation marker DPPIV in intestinal cells; this differentiation-inducing activity is abolished by Fc-TRAIL-R2 chimera pre-incubation.\",\n      \"method\": \"Flow cytometry for receptor expression, Fc-TRAIL-R2 chimera blocking, Western blot for p21/p27/DPPIV, ELISA for cytokines, recombinant TRAIL treatment\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor blocking by Fc chimera with defined molecular readouts in intestinal differentiation model\",\n      \"pmids\": [\"16245299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Apigenin sensitizes lung cancer cells to TRAIL by reprogramming alternative splicing of DR5 (increasing full-length DR5) and c-FLIP (decreasing c-FLIPS) through interaction with RNA-binding proteins hnRNPA2 and MSI2; apigenin also directly binds Hsp70, promoting TRAIL/DISC assembly and triggering apoptosis.\",\n      \"method\": \"RNA-binding protein interaction assays, alternative splicing analysis, Hsp70 binding assay, DISC assembly assays, siRNA knockdown, primary lung cancer cells\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding assays for Hsp70 and hnRNPA2/MSI2, DISC assembly measured, splicing validated\",\n      \"pmids\": [\"33731677\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TNFSF10 (TRAIL) is a homotrimeric TNF superfamily cytokine that induces apoptosis by binding two death-domain-containing receptors (DR4/TRAIL-R1 and DR5/TRAIL-R2), leading to DISC assembly, caspase-8 recruitment/activation, and downstream caspase cascade activation (extrinsic pathway) that can engage the intrinsic mitochondrial pathway; TRAIL also signals non-apoptotic outcomes including NF-κB activation and, in RIP3-expressing cells, necroptosis through RIP1/RIP3; its activity is modulated by decoy receptors (TRAIL-R3, TRAIL-R4), intracellular inhibitors (c-FLIP, IAPs, TRAF2), post-translational modifications (DR4 O-GlcNAcylation at Ser424 required for DISC/necrosome formation), autophagy-mediated receptor degradation, and nuclear trafficking of TRAIL-R2 where it suppresses let-7 miRNA biogenesis via the Microprocessor complex.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper first, then extract discoveries only from KEEP papers.\n\n**Classification notes:**\n- Paper [59] in main corpus: describes \"lncRNA TNFSF10\" — this is case (B) alt-locus product (lncRNA). EXCLUDE.\n- Paper [28] in main corpus: ultramarathon nutrition — EXCLUDE (no relation).\n- Paper [37] in main corpus: oxygen/tissue oxygenation — EXCLUDE (no relation).\n- Paper [38] in main corpus: HBV X protein/tryptase TL2 — EXCLUDE (unrelated gene).\n- Paper [46] in main corpus: planarian organ regeneration — EXCLUDE (no relation).\n- Paper [71] in main corpus: potassium research — EXCLUDE (no relation).\n- Paper [73] in main corpus: nitric oxide/EDRF research history — EXCLUDE (no relation).\n- Paper [83] in main corpus: purinergic signaling/metastases — EXCLUDE (no relation).\n- Paper [88] in main corpus: nucleic acid engineering RNA/DNA — EXCLUDE (no relation).\n- Paper [96] in main corpus: bacteriophage lambda tL2 terminators — EXCLUDE (symbol collision, prokaryotic).\n- Paper [1] in curated list: RANKL/ODF/TRANCE — EXCLUDE (different TNF family member, not TNFSF10).\n- All other papers: KEEP (describe TNFSF10/TRAIL/Apo2L canonical protein).\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"TRAIL (TNFSF10) was identified as a novel type II transmembrane protein of the TNF family, with its C-terminal extracellular domain forming a homotrimeric structure. Both full-length cell-surface TRAIL and picomolar concentrations of soluble TRAIL rapidly induce apoptosis in a wide variety of transformed cell lines. The TRAIL gene is located on chromosome 3q26.\",\n      \"method\": \"cDNA cloning, transfection/overexpression, apoptosis assays with recombinant soluble protein\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning paper with biochemical characterization; foundational discovery replicated extensively\",\n      \"pmids\": [\"8777713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Apo-2L (TRAIL/TNFSF10) is a 281-amino acid type II transmembrane protein whose C-terminal extracellular region forms a homotrimeric subunit structure. Soluble Apo-2L induces apoptosis in lymphoid and non-lymphoid tumor cell lines through a receptor distinct from Fas/Apo-1 and TNF receptors, as soluble Fas and TNF receptors do not inhibit its activity.\",\n      \"method\": \"Recombinant protein expression, apoptosis assays, receptor competition experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with recombinant protein plus receptor competition assays; independent of PMID 8777713\",\n      \"pmids\": [\"8663110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"DR4 (TRAIL-R1), identified as the first receptor for TRAIL, is a member of the TNF-receptor family containing a cytoplasmic death domain capable of engaging the apoptotic machinery. DR4 could not use FADD to transmit the death signal (unlike Fas, TNFR-1, and DR3), suggesting use of distinct proximal signaling machinery. DR4 did not activate NF-κB in the system studied.\",\n      \"method\": \"Receptor cloning, death domain functional assays, FADD interaction studies, NF-κB reporter assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor identification with functional domain characterization; highly cited foundational paper\",\n      \"pmids\": [\"9082980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TRAIL-R2 (DR5) was identified as a distinct receptor for TRAIL via ligand-based affinity purification from human cell lines. TRAIL-R2 contains two extracellular cysteine-rich repeats and a cytoplasmic death domain. Unlike TRAIL-R1, TRAIL-R2 mediates apoptosis via the intracellular adaptor molecule FADD/MORT1. The TRAIL-R2 gene maps to chromosome 8p22-21.\",\n      \"method\": \"Ligand-based affinity purification, molecular cloning, FADD interaction assays, Fc fusion protein blocking experiments\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — protein purified directly from cell lines, cloned, and functionally characterized with multiple orthogonal methods\",\n      \"pmids\": [\"9311998\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TRID (TRAIL-R3/DcR1), an antagonist decoy receptor for TRAIL, was identified with an extracellular TRAIL-binding domain and transmembrane domain but no intracellular signaling domain. Ectopic expression of TRID protected cells from TRAIL-induced apoptosis. A second death domain-containing receptor DR5 preferentially engaged a FLICE (caspase-8)-related death protease.\",\n      \"method\": \"Gene cloning, ectopic expression, apoptosis protection assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional rescue experiment demonstrating decoy receptor mechanism; highly cited\",\n      \"pmids\": [\"9242610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TRAIL-R2 (DR5) and TRAIL-R3 were characterized: TRAIL-R2 is structurally similar to TRAIL-R1 and capable of inducing apoptosis; TRAIL-R3 does not promote cell death, is highly glycosylated, and is membrane-bound via a GPI anchor. TRAIL-R3 has TAPE repeats extending its structure. All three receptors bind TRAIL with similar affinity.\",\n      \"method\": \"Receptor cloning, apoptosis assays, binding affinity measurements, glycosylation and GPI anchor characterization\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal biochemical methods characterizing receptor structure and function\",\n      \"pmids\": [\"9373179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TRAIL-R4, a fourth TRAIL receptor, was cloned and characterized. TRAIL-R4 retains an incomplete death domain (one-third of consensus motif) and activates NF-κB similarly to TRAIL-R1/R2, but cannot induce apoptosis. Transient overexpression of TRAIL-R4 in TRAIL-sensitive cells conferred complete protection from TRAIL-mediated killing. TRAIL-R4 gene maps to chromosome 8p22-21, clustered with other TRAIL receptor genes.\",\n      \"method\": \"Gene cloning, NF-κB reporter assays, apoptosis assays, overexpression protection experiments\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional overexpression experiments with NF-κB and apoptosis assays; highly cited\",\n      \"pmids\": [\"9430226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TRAIL-R1 (DR4) and TRAIL-R2 (DR5) both bind the adaptor molecules FADD and TRADD, and both death signals are blocked by dominant-negative FADD and by the FLICE-inhibitory protein FLIP. TRAIL-R1 can associate with TRAIL-R2, suggesting possible signaling through heteroreceptor complexes. Recruitment of TRADD explains the potent NF-κB activation observed from TRAIL receptors.\",\n      \"method\": \"Co-immunoprecipitation, dominant-negative FADD and FLIP overexpression, NF-κB reporter assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP plus genetic (dominant-negative) epistasis; highly cited\",\n      \"pmids\": [\"9430228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Two additional TRAIL receptors, TRAIL-R2 (DR5, containing a death domain) and TRAIL-R3 (lacking a death domain), were identified. DR5 engages the apoptotic pathway independently of FADD/MORT1. TRAIL-R3, by competing for TRAIL binding, inhibits TRAIL-induced apoptosis, functioning as an antagonistic decoy receptor.\",\n      \"method\": \"cDNA library screening, apoptosis assays, FADD interaction studies, competition binding assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays establishing decoy mechanism; highly cited\",\n      \"pmids\": [\"9325248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TRAIL-R3 (DcR1) was cloned and shown to be a GPI-linked plasma membrane protein with high-affinity TRAIL binding but lacking a cytoplasmic domain. TRAIL-R3 does not induce apoptosis and shows restricted expression in peripheral blood lymphocytes and spleen. The TRAIL-R3 gene maps to chromosome 8p22-21.\",\n      \"method\": \"cDNA cloning, quantitative binding studies, GPI-anchor characterization, apoptosis assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — biochemical characterization with quantitative binding and functional assays\",\n      \"pmids\": [\"9314565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The crystal structure of the Apo2L/TRAIL homotrimer in complex with the ectodomain of DR5 was solved. Three elongated DR5 receptors bind in long crevices between pairs of monomers of the trimeric ligand. The binding interface is divided into two distinct patches (near the membrane-proximal and membrane-distal ends), both containing residues critical for high-affinity binding. Comparison to the lymphotoxin-receptor complex revealed general principles of binding in the TNF receptor superfamily.\",\n      \"method\": \"X-ray crystallography\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure; foundational structural paper\",\n      \"pmids\": [\"10549288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"FADD/MORT1 and caspase-8 are recruited to both TRAIL-R1 and TRAIL-R2 in a ligand-dependent manner to form the TRAIL death-inducing signaling complex (DISC). FADD/MORT1 and caspase-8 are recruited to the two TRAIL receptors independently of each other. FADD- and caspase-8-deficient Jurkat cells expressing only TRAIL-R2 were resistant to TRAIL-induced apoptosis, establishing that both proteins are essential for TRAIL-R2-mediated apoptosis.\",\n      \"method\": \"Native DISC immunoprecipitation, differential receptor precipitation, genetic knockout cell lines (FADD-deficient, caspase-8-deficient)\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — native DISC biochemistry combined with genetic KO cells; highly cited\",\n      \"pmids\": [\"10894160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Caspase-10 is recruited to both the native TRAIL DISC and the native CD95 DISC in a FADD-dependent manner and is activated at these complexes. However, caspase-10 cannot functionally substitute for caspase-8: caspase-8-deficient cells could not be rescued by caspase-10 overexpression. Caspase-10 is cleaved during CD95-induced apoptosis of activated T cells.\",\n      \"method\": \"Native DISC immunoprecipitation, genetic knockout cells (FADD-deficient), caspase-10 overexpression rescue experiments, primary T cell assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — native DISC biochemistry plus genetic epistasis; well-controlled\",\n      \"pmids\": [\"12198154\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"FOXO forkhead transcription factors FKHRL1 and FKHR directly regulate TRAIL (TNFSF10) expression. The FKHRL1-responsive element in the TRAIL promoter was mapped to nucleotides -138 to -121. Loss of PTEN in prostate cancer leads to decreased FOXO activity and reduced TRAIL expression in metastatic prostate tumors, linking the PI3K-Akt pathway to TRAIL gene regulation.\",\n      \"method\": \"Microarray gene expression, adenoviral FOXO overexpression, TRAIL promoter reporter constructs, chromatin analysis, human tumor immunohistochemistry\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — promoter mapping with deletion constructs plus in vivo tumor validation\",\n      \"pmids\": [\"12351634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"PPAR-γ ligands sensitize tumor cells (but not normal cells) to TRAIL-induced apoptosis by reducing FLIP protein levels through ubiquitination and proteasome-dependent degradation, without affecting FLIP mRNA. This mechanism is PPAR-γ-independent (active with both agonists and antagonists and dominant-negative PPAR-γ) and does not involve NF-κB.\",\n      \"method\": \"PPAR-γ agonist/antagonist treatment, dominant-negative PPAR-γ, FLIP ubiquitination assays, proteasome inhibitor experiments, mRNA vs. protein analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches ruling out PPAR-γ and NF-κB dependence and establishing ubiquitin-proteasome mechanism\",\n      \"pmids\": [\"11940602\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"HDAC inhibitors induce TRAIL (TNFSF10) expression in acute myeloid leukemia (AML) cells by directly activating the TNFSF10 promoter, thereby triggering tumor-selective death signaling. RNA interference showed that TRAIL induction, p21 induction, and differentiation are separable activities of HDACIs. Normal CD34+ progenitor cells did not undergo apoptosis.\",\n      \"method\": \"HDAC inhibitor treatment, TRAIL promoter reporter assays, RNA interference (siRNA), chromatin immunoprecipitation, primary AML blast assays\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — promoter-level mechanistic evidence with RNAi and primary patient cells; highly cited\",\n      \"pmids\": [\"15619633\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"FLIP protein potently blocks TRAIL-mediated cell death by interfering with caspase-8 activation at the DISC. Pharmacologic down-regulation of FLIP sensitizes tumor cells to TRAIL-induced apoptosis.\",\n      \"method\": \"FLIP overexpression and knockdown, caspase-8 activation assays, apoptosis assays\",\n      \"journal\": \"Vitamins and hormones\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — review synthesizing mechanistic studies; single review paper without primary data\",\n      \"pmids\": [\"15110178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TRAIL-receptor-selective mutant forms of TRAIL were synthesized that selectively bind TRAIL-R1 or TRAIL-R2. The selectivity in inducing apoptosis is due to selective receptor binding and formation of a death-inducing signaling complex (DISC) with the cognate receptor. Using these mutants, primary chronic lymphocytic leukemia and mantle cell lymphoma cells were shown to signal apoptosis almost exclusively through TRAIL-R1.\",\n      \"method\": \"Synthetic receptor-selective TRAIL mutants, apoptosis assays, DISC formation analysis, primary patient CLL and MCL cells\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — engineered mutant ligands with DISC biochemistry and primary patient cell validation\",\n      \"pmids\": [\"16357130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"O-glycosylation of death receptors DR4 and DR5 by the peptidyl O-glycosyltransferase GALNT14 controls tumor-cell sensitivity to Apo2L/TRAIL. Biochemical analysis identified O-(GalNAc-Gal-sialic acid) structures on the DR5 ectodomain at conserved extracellular sites. Progressive mutation of these sites attenuated apoptotic signaling. O-glycosylation promoted ligand-stimulated clustering of DR4 and DR5, which mediated recruitment and activation of caspase-8.\",\n      \"method\": \"GALNT14 RNAi and overexpression, DR5 mass spectrometry glycosylation mapping, site-directed mutagenesis of O-glycosylation sites, receptor clustering assays, caspase-8 activation assays\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical glycan mapping plus mutagenesis plus functional clustering assays; highly cited\",\n      \"pmids\": [\"17167167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The transcription factor Sp1 is responsible for TRAIL (TNFSF10) induction by the HDAC inhibitor MS275 alone or in combination with Adriamycin in breast cancer cells. Chromatin immunoprecipitation confirmed Sp1 binding to the TRAIL promoter. Knockdown of TRAIL by siRNA decreased MS275-mediated Adriamycin-induced caspase activation, and Sp1-knockout MEFs were resistant to combined treatment.\",\n      \"method\": \"TRAIL promoter reporter constructs, chromatin immunoprecipitation, Sp1 siRNA knockdown, Sp1-knockout mouse embryonic stem cells, caspase activation assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — promoter mapping with ChIP, RNAi, and genetic KO cells with multiple readouts\",\n      \"pmids\": [\"18701496\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"TRAIL-induced autophagy in untransformed epithelial cells is mediated by AMPK, which inhibits mTORC1. TRAIL-induced AMPK activation is independent of LKB1 and CaMKK-β but depends on TAK1 and TAK1-binding subunit 2. This cytoprotective autophagy pathway contributes to the resistance of normal (untransformed) cells to TRAIL-induced apoptosis.\",\n      \"method\": \"Genetic knockdown (siRNA for TAK1, LKB1, CaMKK-β), AMPK activity assays, mTORC1 signaling assays, autophagy monitoring, apoptosis assays in normal vs. transformed cells\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple RNAi knockdowns establishing epistasis; published in high-impact journal\",\n      \"pmids\": [\"19197243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Death receptor ligation by TRAIL/DR4/DR5 induces polyubiquitination of caspase-8 through a cullin3 (CUL3)-based E3 ligase that is recruited to the DISC. CUL3-mediated caspase-8 polyubiquitination requires RBX1; the deubiquitinase A20 reverses this modification. The ubiquitin-binding protein p62/sequestosome-1 promotes aggregation of CUL3-modified caspase-8 within p62 foci, leading to full activation, processing, and commitment to apoptosis.\",\n      \"method\": \"Co-immunoprecipitation of native DISC, ubiquitination assays, CUL3/RBX1/A20/p62 RNAi knockdown, caspase-8 processing assays, confocal microscopy of p62 foci\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mechanistic reconstitution with multiple orthogonal methods identifying a new PTM (ubiquitination) and its writer/eraser/reader; highly cited\",\n      \"pmids\": [\"19427028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. TRAIL-R2 (but not TRAIL-R1, R3, or R4) is expressed throughout erythroid differentiation from CD34+ progenitors. TRAIL stimulates ERK1/2 (but not p38 MAPK or JNK) signaling in erythroblasts, and the ERK inhibitor PD98059 (but not the pan-caspase inhibitor z-VAD or p38 inhibitor SB203580) reverses the anti-differentiative effect of TRAIL on erythroid maturation.\",\n      \"method\": \"Flow cytometry (receptor expression), recombinant TRAIL treatment, ERK/p38/JNK phosphorylation assays, pharmacological pathway inhibitors, morphological differentiation assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — specific pathway inhibitors with selective pharmacological dissection; primary CD34+ cell system\",\n      \"pmids\": [\"12969966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TRAIL-R4 expressed endogenously or ectopically inhibits TRAIL-induced apoptosis. Chemotherapy restores TRAIL sensitivity in TRAIL-R4-expressing cells primarily at the DISC level through enhanced caspase-8 recruitment and activation. The sensitization is compromised by c-FLIP expression and is independent of mitochondria. TRAIL-R4 cooperates with c-FLIP to inhibit TRAIL-induced cell death, and TRAIL-R4 expression prevents TRAIL-induced tumor regression in vivo.\",\n      \"method\": \"Ectopic TRAIL-R4 expression, DISC immunoprecipitation, caspase-8 recruitment assays, c-FLIP manipulation, mitochondria-independent cell death assays, xenograft tumor models\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — native DISC biochemistry plus in vivo xenograft validation\",\n      \"pmids\": [\"21072058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TRAF2 acts as a negative regulator of TRAIL-induced apoptosis and necroptosis. TRAF2 knockdown sensitizes keratinocytes to TRAIL-induced apoptosis. In cells lacking RIP3, TRAF2 knockdown sensitizes to TRAIL-induced caspase-dependent apoptosis. In RIP3-expressing cells, TRAF2 knockdown additionally sensitizes to TRAIL-induced necroptosis. TRAIL-induced necroptosis is independent of endogenous TNF/TNFR signaling. TWEAK-mediated depletion of cytosolic TRAF2 complexes strongly sensitizes for TRAIL-induced necroptosis.\",\n      \"method\": \"TRAF2 siRNA knockdown, zVAD-fmk (pan-caspase inhibitor) protection assays, necrostatin-1 (RIP1 inhibitor), RIP3-stable transfectants, TNFR2-Fc and anti-TNFα blocking experiments\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockdown combined with pharmacological inhibitors and RIP3 reconstitution system dissecting apoptosis vs. necroptosis\",\n      \"pmids\": [\"25299769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"DAPK2 (death-associated protein kinase 2) is a modulator of TRAIL signaling. Genetic ablation of DAPK2 by RNAi causes NF-κB phosphorylation and transcriptional activation, leading to induction of DR4 and DR5 expression. Increased DR4/DR5 surface expression sensitizes resistant cancer cells to TRAIL-induced killing in a p53-independent manner.\",\n      \"method\": \"DAPK2 siRNA knockdown, NF-κB reporter and phosphorylation assays, DR4/DR5 surface flow cytometry, p53-deficient cell lines, TRAIL cytotoxicity assays\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RNAi knockdown with pathway reporter and surface receptor quantification; single lab\",\n      \"pmids\": [\"25012503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Poly-ADP-ribosylation of HMGB1 by PARP1 is required for TRAIL (TNFSF10)-induced HMGB1 cytoplasmic translocation and subsequent HMGB1-BECN1 complex formation, which drives cytoprotective autophagy. Pharmacological inhibition or knockdown of PARP1 inhibits HMGB1-mediated autophagy, increases apoptosis, and enhances TRAIL anticancer activity in vitro and in a tumor model. Thus PARP1-dependent HMGB1 ADP-ribosylation maintains a homeostatic balance between autophagy and apoptosis during TRAIL signaling.\",\n      \"method\": \"PARP1 pharmacological inhibition and siRNA knockdown, HMGB1 ADP-ribosylation assays, co-immunoprecipitation (HMGB1-BECN1 complex), autophagy monitoring, apoptosis assays, subcutaneous tumor model\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — PTM identification (ADP-ribosylation) with Co-IP of downstream complex and in vivo validation\",\n      \"pmids\": [\"25607248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Hepatitis B virus X protein (HBx) evades TRAIL (TNFSF10)-mediated antiviral immunity by promoting autophagy-mediated lysosomal degradation of TNFRSF10B (DR5). HBx directly interacts with TNFRSF10B and recruits it to phagophores (autophagosome precursors), acting as an autophagy receptor-like molecule that promotes TNFRSF10B association with LC3B. HBx also functions as an autophagy inducer. Inhibition of autophagy enhances susceptibility of HBx-infected hepatocytes to TRAIL.\",\n      \"method\": \"Immunoprecipitation and GST affinity isolation (HBx-TNFRSF10B interaction), tandem-fluorescence LC3B assay, LC3B/SQSTM1 immunoblotting, LC3B knockdown, pharmacological autophagy inhibition, liver tissue from chronic HBV patients\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct protein interaction (GST pulldown + Co-IP) combined with autophagy functional assays and patient tissue validation\",\n      \"pmids\": [\"27740879\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TRAIL-mediated necroptosis shares signaling components with TNF-mediated necroptosis including acid and neutral sphingomyelinases, HtrA2/Omi, Atg5, and vacuolar H+-ATPase. However, TRAIL-mediated necroptosis differs from TNF-mediated necroptosis in being independent of UCH-L1 and Atg16L1, and does not require receptor internalization or endosome-lysosome acidification. Bcl-XL overexpression specifically diminishes TRAIL-induced necroptosis, suggesting differential mitochondrial involvement. Depletion of p38α increases both types of cell death.\",\n      \"method\": \"siRNA knockdown of signaling components, pharmacological inhibitors, Bcl-2/Bcl-XL overexpression, RIP3-expressing cell systems, necroptosis quantification\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic siRNA screen combined with overexpression experiments in defined cell systems\",\n      \"pmids\": [\"27528614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DR4 (TRAIL-R1) is O-GlcNAcylated at Ser424 within its death domain, and this modification is essential for TRAIL-induced apoptosis and necrosis. Ser424 mutations identified from cancer patients caused TRAIL resistance. O-GlcNAcylation-defective DR4 failed to form DISC/necrosome and could not translocate to aggregated receptor-clustering platforms. DR5 is not O-GlcNAcylated by TRAIL treatment, discriminating DR4 from DR5-mediated signaling. Promoting DR4 O-GlcNAcylation (with 2-deoxy-D-glucose or high glucose) sensitized resistant cancer cells to TRAIL.\",\n      \"method\": \"O-GlcNAc transferase knockdown, DR4 site-directed mutagenesis (Ser424), cancer patient cDNA library screen (TCGA), DR5-neutralizing antibody, DISC/necrosome co-immunoprecipitation, receptor clustering assays, glucose-modulated O-GlcNAcylation\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — identifies a novel PTM (O-GlcNAcylation) on TRAIL-R1 with mutagenesis, functional rescue, and mechanistic dissection of DISC formation\",\n      \"pmids\": [\"30987996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Nuclear TRAIL-R2 (nTRAIL-R2) originates from the plasma membrane via TRAIL-dependent clathrin-mediated endocytosis. nTRAIL-R2 interacts with the nucleo-cytoplasmic shuttle protein Exportin-1/CRM-1; mutation of a putative nuclear export sequence (NES) in TRAIL-R2 or inhibition of CRM-1 by Leptomycin-B causes nuclear accumulation of TRAIL-R2. Nuclear TRAIL-R2 inhibits processing of primary let-7 miRNA (pri-let-7) by interacting with accessory proteins of the Microprocessor complex, thereby decreasing mature let-7 and enhancing malignancy.\",\n      \"method\": \"Co-immunoprecipitation (nTRAIL-R2 with Microprocessor components), NES mutagenesis, Leptomycin-B CRM-1 inhibition, nuclear fractionation, let-7 miRNA processing assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — review/synthesis paper covering multiple studies; primary data from referenced works\",\n      \"pmids\": [\"25165876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TRAIL induces nuclear translocation of TRAIL-R1 and TRAIL-R2 from the plasma membrane via clathrin-dependent endocytosis in a TRAIL-dependent manner. Nuclear trafficking is rapid and involves interaction of nTRAIL-R2 with Exportin-1/CRM-1. NES mutation in TRAIL-R2 or CRM-1 inhibition (Leptomycin-B) causes nuclear accumulation. TRAIL-R1 and TRAIL-R2 constitutively localize to chromatin, which is strongly enhanced by TRAIL treatment.\",\n      \"method\": \"Cell surface biotinylation and intracellular tracking, clathrin inhibition, co-immunoprecipitation (TRAIL-R2/Exportin-1), NES mutagenesis, Leptomycin-B treatment, chromatin fractionation, immunofluorescence\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — surface biotinylation tracking plus genetic and pharmacological tools establishing nuclear trafficking mechanism\",\n      \"pmids\": [\"31416165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A subset of LAMP1+TRAIL+ astrocytes limits CNS inflammation by inducing T cell apoptosis through TRAIL-DR5 signaling. In homeostatic conditions, TRAIL expression in astrocytes is driven by IFNγ produced by meningeal NK cells, which is modulated by the gut microbiome. T cells and microglia repress TRAIL expression in astrocytes during inflammation. CRISPR-Cas9-based in vivo genetic perturbations confirmed the role of astrocytic TRAIL in T cell killing.\",\n      \"method\": \"High-throughput flow cytometry screening, single-cell RNA sequencing, CRISPR-Cas9 in vivo genetic perturbations, T cell apoptosis assays (TRAIL-DR5 blocking), germ-free mouse models\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR-Cas9 in vivo perturbation with multiple orthogonal methods; published in Nature\",\n      \"pmids\": [\"33408417\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"In intestinal epithelial cells, TRAIL promotes differentiation rather than apoptosis despite expression of TRAIL-R1 and TRAIL-R2. TRAIL increases expression of cyclin-dependent kinase inhibitors p21 and p27 and the differentiation marker DPPIV. The differentiation-inducing activity was abolished by pre-incubation with Fc-TRAIL-R2 chimera, establishing TRAIL-R2 as the functional receptor mediating this non-apoptotic effect.\",\n      \"method\": \"Flow cytometry (receptor expression), recombinant TRAIL treatment, Fc-TRAIL-R2 chimera blocking, cell cycle analysis (p21/p27/DPPIV expression), differentiation assays\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor-blocking experiment plus differentiation marker analysis; single lab\",\n      \"pmids\": [\"16245299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Megakaryocytes synthesize TRAIL during differentiation via increased transcriptional activity of the TRAIL promoter, and activated platelets express both membrane-bound and soluble TRAIL. Lineage-specific upregulation of TRAIL expression during megakaryocyte differentiation is mediated at the transcriptional level.\",\n      \"method\": \"Immunoprecipitation, ELISA, flow cytometry, RT-PCR, TRAIL promoter/reporter transient transfection, in vitro megakaryocyte differentiation\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods establishing lineage-specific transcriptional regulation; single lab\",\n      \"pmids\": [\"15539085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"miR-24-3p from M2 macrophage-derived exosomes targets and inhibits Tnfsf10 (TRAIL) mRNA in cardiomyocytes. A direct binding relationship between miR-24-3p and the Tnfsf10 3'UTR was demonstrated. In a septic mouse model, Tnfsf10 expression is elevated in myocardial tissue; exosomal miR-24-3p or Tnfsf10 siRNA knockdown improved cardiac function and reduced cardiomyocyte apoptosis.\",\n      \"method\": \"Luciferase reporter assay (miR-24-3p binding to Tnfsf10 3'UTR), exosome isolation and miR-24-3p modification, Tnfsf10 siRNA knockdown, LPS-induced sepsis mouse model, cardiac function assays\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct 3'UTR binding assay plus in vivo model; single lab\",\n      \"pmids\": [\"34933177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Neutralization of TNFSF10 (TRAIL) by a monoclonal antibody in the 3xTg-AD Alzheimer's disease mouse model attenuates amyloid-β-induced neurotoxicity, improves cognitive function (Morris water maze, novel object recognition), and reduces expression of TNFSF10, amyloid-β, inflammatory mediators, and GFAP in the hippocampus. This establishes TNFSF10 as a mediator of amyloid-β neurotoxicity.\",\n      \"method\": \"Neutralizing monoclonal antibody administration, transgenic mouse model (3xTg-AD), Morris water maze and novel object recognition behavioral tests, protein expression analysis (TNFSF10, Aβ, GFAP, inflammatory mediators)\",\n      \"journal\": \"Brain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo neutralization with behavioral and biochemical readouts; single lab\",\n      \"pmids\": [\"25472798\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"TRAIL-mediated apoptosis of hepatocytes in vivo is triggered through TRAIL receptor DR5 and requires viral infection; uninfected hepatocytes in vivo are resistant to TRAIL-mediated apoptosis. Overexpression of TRAIL in the liver after viral infection is independent of lymphocytes, NK cells, and Kupffer cells, indicating a paracrine hepatocyte-autonomous mechanism against virally infected cells.\",\n      \"method\": \"Adenoviral hepatitis mouse model, DR5 blocking/knockout studies, liver histology, NK/lymphocyte depletion experiments, in vitro vs. in vivo TRAIL sensitivity comparison\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo mouse model with cell depletion experiments; mechanistic insight into tissue-specific TRAIL resistance\",\n      \"pmids\": [\"12475902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Dengue virus (DV) induces TRAIL expression in immune cells and endothelial cells via an intact type I interferon signaling pathway. TRAIL functions as an antiviral protein: anti-TRAIL antibody treatment increased DV RNA accumulation, while recombinant TRAIL inhibited DV titers in dendritic cells by an apoptosis-independent mechanism.\",\n      \"method\": \"Affymetrix GeneChip microarray, anti-TRAIL antibody treatment, recombinant TRAIL treatment, DV RNA quantification and titer measurement, interferon pathway blockade\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — antibody blocking and recombinant protein rescue experiments; apoptosis-independence established\",\n      \"pmids\": [\"17913827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"NF-κB transcription factors are key regulators of TRAIL expression in lymphocytes. TRAIL transcription is activated through an interferon-response element in its promoter. Decoy receptors TRAIL-R3/DcR1 and TRAIL-R4/DcR2 lack functional death domains and do not mediate apoptosis, providing a regulatory mechanism for differential sensitivity.\",\n      \"method\": \"NF-κB reporter assays, promoter analysis with interferon-response element, TRAIL receptor expression studies\",\n      \"journal\": \"Cytokine & growth factor reviews\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — review article summarizing mechanistic findings from other studies; no new primary data\",\n      \"pmids\": [\"12486874\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TNFSF10 (TRAIL/Apo2L) is a homotrimeric type II transmembrane cytokine that induces apoptosis by binding two death-domain-containing receptors (TRAIL-R1/DR4 and TRAIL-R2/DR5), which recruit FADD and caspase-8 (and caspase-10 in a FADD-dependent but non-redundant manner) into a death-inducing signaling complex (DISC); full caspase-8 activation requires CUL3-mediated polyubiquitination and p62-dependent aggregation, and is further regulated by post-translational modifications including O-GlcNAcylation of DR4-Ser424 and O-glycosylation of DR4/DR5 ectodomains (which promote receptor clustering); three decoy/non-apoptotic receptors (TRAIL-R3, TRAIL-R4, and OPG) modulate signaling, while intracellular regulators including FLIP, IAPs, TRAF2, and DAPK2 control pathway output; TRAIL can also signal non-apoptotically via ERK (in erythroid differentiation), TAK1-AMPK (cytoprotective autophagy), NF-κB, and TRAIL-R2 nuclear trafficking to inhibit let-7 miRNA maturation; TRAIL gene expression is transcriptionally regulated by FOXO forkhead factors (via the PI3K-PTEN-Akt axis), NF-κB, interferon-response elements, Sp1 (under HDAC inhibitor treatment), and HDAC inhibitors acting directly on the TNFSF10 promoter.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TNFSF10 (TRAIL) is a homotrimeric TNF superfamily cytokine that functions as a key effector of apoptosis, necroptosis, immune surveillance, and cellular differentiation through engagement of death-domain-containing receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2). Ligand binding triggers assembly of the death-inducing signalling complex (DISC), recruiting FADD and activating caspase-8, which engages both the extrinsic caspase cascade and the intrinsic mitochondrial apoptotic pathway; in RIP3-expressing cells, TRAIL instead drives necroptosis via RIP1/RIP3, a pathway mechanistically distinct from TNF-induced necroptosis and requiring sphingomyelinases and HtrA2/Omi [PMID:9082980, PMID:9311998, PMID:12655296, PMID:27528614]. TRAIL signaling is modulated at multiple levels: decoy receptors TRAIL-R3 and TRAIL-R4 compete for ligand binding, intracellular inhibitors c-FLIP and IAPs suppress caspase activation at the DISC, O-GlcNAcylation of DR4 at Ser424 is required for DISC/necrosome assembly, and autophagy-mediated lysosomal degradation of DR5 attenuates responsiveness [PMID:9373179, PMID:21072058, PMID:15353805, PMID:30987996, PMID:27740879]. Beyond cell death, TRAIL activates NF-κB, promotes intestinal epithelial differentiation via p21/p27 induction, regulates erythroid maturation through ERK1/2 signaling, limits CNS inflammation through IFNγ-driven astrocyte expression that induces T cell apoptosis, and exerts antiviral activity against dengue virus through an apoptosis-independent mechanism [PMID:12655296, PMID:16245299, PMID:12969966, PMID:33408417, PMID:17913827].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Identification of DR4 and DR5 as the two death-domain-containing receptors for TRAIL established the molecular basis for TRAIL-induced apoptosis and revealed that DR5 signals through FADD while DR4 initially appeared to use distinct proximal machinery.\",\n      \"evidence\": \"Homology-based receptor cloning, ligand-based affinity purification, FADD interaction assays, functional overexpression in human cells\",\n      \"pmids\": [\"9082980\", \"9311998\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether DR4 ultimately uses FADD (later resolved)\", \"Structural basis for receptor selectivity of TRAIL trimer\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Discovery of the decoy receptor TRAIL-R3, which binds TRAIL with similar affinity but lacks a functional death domain, revealed that TRAIL signaling is subject to competitive receptor-level regulation.\",\n      \"evidence\": \"Receptor characterization, binding affinity measurements, structural analysis of GPI-anchored receptor\",\n      \"pmids\": [\"9373179\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo physiological role of decoy receptors\", \"Relative stoichiometry of death vs decoy receptors on target cells\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Biochemical characterization of the TRAIL DISC established the central signaling platform model: TRAIL induces DISC formation at DR4/DR5, recruiting caspase-8 for extrinsic apoptosis, with cross-talk to mitochondrial (intrinsic) pathway and NF-κB activation providing a framework for understanding diverse cellular outcomes.\",\n      \"evidence\": \"DISC biochemical isolation, caspase activation assays, NF-κB reporter assays across multiple cell systems\",\n      \"pmids\": [\"12655296\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular determinants dictating apoptosis vs NF-κB signaling outcome\", \"Role of lipid rafts/receptor clustering in DISC formation\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstration that TRAIL promotes intestinal epithelial differentiation via p21/p27 induction and accelerates neutrophil apoptosis through DR5 extended TRAIL's biology beyond tumor killing to homeostatic tissue functions.\",\n      \"evidence\": \"Fc-TRAIL-R2 blocking chimera with Western blot readouts in intestinal cells; DR5-specific blocking antibodies in primary human neutrophils\",\n      \"pmids\": [\"16245299\", \"12517970\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling pathway from DR5 to p21/p27 induction not mapped\", \"In vivo relevance of TRAIL in gut epithelial turnover\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"A Smac mimetic that antagonizes XIAP, cIAP-1, and cIAP-2 potentiated TRAIL-induced caspase activation, placing IAP proteins as temporal checkpoints within the TRAIL apoptotic cascade and identifying a therapeutic strategy.\",\n      \"evidence\": \"In vitro IAP binding assays, caspase activation kinetics, apoptosis assays in multiple human cancer cell lines\",\n      \"pmids\": [\"15353805\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of individual IAP family members\", \"Whether IAP antagonism alters non-apoptotic TRAIL signaling\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Receptor-selective TRAIL mutants demonstrated that primary CLL and mantle cell lymphoma cells signal apoptosis almost exclusively through DR4, not DR5, establishing that receptor preference is context-dependent and disease-relevant.\",\n      \"evidence\": \"DR4- and DR5-selective TRAIL protein mutants, DISC formation assays, apoptosis in primary patient-derived cells\",\n      \"pmids\": [\"16357130\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for DR4 preference in hematological malignancies\", \"Whether receptor preference reflects expression levels or signaling efficiency\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"TRAIL-R4 was shown to inhibit apoptosis at the DISC level by impairing caspase-8 recruitment, cooperating with c-FLIP; chemotherapy overcame this block, mechanistically explaining combinatorial therapeutic approaches.\",\n      \"evidence\": \"DISC analysis with ectopic and endogenous TRAIL-R4 expression, caspase-8 recruitment quantification, tumor xenograft validation\",\n      \"pmids\": [\"21072058\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TRAIL-R4 hetero-oligomerizes with DR4/DR5 within the DISC\", \"TRAIL-R4 role in normal physiology\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"TRAF2 was identified as a negative regulator of both TRAIL-induced apoptosis and necroptosis; in RIP3-expressing cells, TRAF2 loss unmasked a TRAIL-RIP1/RIP3-dependent necroptotic pathway independent of autocrine TNF signaling, establishing TRAIL as a direct necroptosis inducer.\",\n      \"evidence\": \"TRAF2 siRNA, zVAD-fmk, necrostatin-1, stable RIP3-expressing HeLa cells, TNF-blocking antibodies\",\n      \"pmids\": [\"25299769\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TRAF2 acts by K48-linked ubiquitination of RIP1 or other mechanism\", \"Physiological contexts where TRAIL necroptosis predominates\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Nuclear TRAIL-R2 was found to inhibit let-7 miRNA maturation by interacting with the Microprocessor complex, and its nuclear trafficking from the plasma membrane depends on clathrin-mediated endocytosis and CRM-1/Exportin-1, revealing a non-canonical, non-apoptotic function for a TRAIL receptor.\",\n      \"evidence\": \"Cell surface biotinylation tracking, immunoprecipitation with Microprocessor components, CRM-1 inhibition, NES mutagenesis\",\n      \"pmids\": [\"25165876\", \"31416165\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TRAIL ligand binding enhances or inhibits nuclear import\", \"Global impact on miRNA-dependent gene regulation\", \"Whether DR4 undergoes analogous nuclear trafficking\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Detailed pathway dissection showed TRAIL-mediated necroptosis requires acid/neutral sphingomyelinases, HtrA2/Omi, and Atg5 but not PARP-1, UCH-L1, or receptor internalization, distinguishing it mechanistically from TNF-mediated necroptosis; Bcl-XL overexpression selectively suppressed TRAIL necroptosis.\",\n      \"evidence\": \"Genetic knockdown/overexpression of individual pathway components, pharmacological inhibitors, RIP3-overexpressing cells, apoptosis/necroptosis discrimination\",\n      \"pmids\": [\"27528614\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How sphingomyelinases connect to RIP1/RIP3 necrosome\", \"In vivo validation of TRAIL-specific necroptotic pathway\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"HBV protein HBx was shown to promote autophagy-mediated lysosomal degradation of DR5 by directly recruiting it to phagophores via LC3B interaction, revealing autophagy as a mechanism of TRAIL resistance in viral hepatitis.\",\n      \"evidence\": \"GST pulldown, co-immunoprecipitation, tandem-fluorescence LC3B microscopy, LC3B knockdown, pharmacological autophagy inhibition\",\n      \"pmids\": [\"27740879\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether endogenous autophagy receptors similarly target DR5 in non-viral contexts\", \"Structural basis of HBx-DR5-LC3B ternary interaction\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"O-GlcNAcylation of DR4 at Ser424 within its death domain was identified as a post-translational requirement for DISC and necrosome assembly, receptor clustering, and both apoptotic and necroptotic TRAIL signaling, providing a metabolic rheostat for TRAIL sensitivity.\",\n      \"evidence\": \"Ser424 mutagenesis, OGT knockdown, 2-deoxy-D-glucose modulation, DISC/necrosome formation assays in multiple cancer cell models\",\n      \"pmids\": [\"30987996\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Enzyme(s) responsible for DR4 de-O-GlcNAcylation\", \"Whether O-GlcNAcylation state varies across tissues or tumor types in vivo\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"LAMP1+TRAIL+ astrocytes in the CNS were identified as anti-inflammatory effectors that kill T cells via TRAIL-DR5 signaling, with astrocyte TRAIL expression driven by IFNγ from meningeal NK cells licensed by the gut microbiome, linking systemic immune regulation to TRAIL-mediated CNS homeostasis.\",\n      \"evidence\": \"High-throughput flow cytometry, scRNA-seq, CRISPR-Cas9 cell-type-specific in vivo perturbation in mouse EAE model\",\n      \"pmids\": [\"33408417\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether human astrocyte TRAIL expression follows same microbiome-NK-IFNγ axis\", \"Whether TRAIL-expressing astrocytes also regulate myeloid cell survival\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis for TRAIL trimer engagement of heteromeric receptor complexes (e.g., DR4/DR5/TRAIL-R4 mixed DISCs), the in vivo physiological balance between apoptotic, necroptotic, and non-death signaling outputs in different tissues, and the functional significance of nuclear DR5/let-7 regulation in cancer biology remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of heteromeric TRAIL receptor complexes\", \"In vivo quantitative contribution of necroptosis vs apoptosis to TRAIL-mediated tumor control\", \"Physiological relevance of nuclear DR5-let-7 axis in primary tumors\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 3, 5]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 7, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 2, 16]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 1, 3, 4, 5, 6, 7, 9, 12, 20]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [15, 21]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 7, 11, 18]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [10, 17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"TNFRSF10A\",\n      \"TNFRSF10B\",\n      \"TNFRSF10C\",\n      \"TNFRSF10D\",\n      \"FADD\",\n      \"TRAF2\",\n      \"RIPK1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"TNFSF10 (TRAIL/Apo2L) is a homotrimeric type II transmembrane cytokine of the TNF superfamily that induces apoptosis in transformed cells by engaging the death-domain-containing receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2), which recruit FADD and caspase-8 into a death-inducing signaling complex (DISC); full caspase-8 activation requires CUL3-mediated polyubiquitination and p62-dependent aggregation, and is modulated by post-translational modifications including O-glycosylation of DR4/DR5 ectodomains (promoting receptor clustering) and O-GlcNAcylation of DR4-Ser424 [PMID:8777713, PMID:10894160, PMID:19427028, PMID:17167167, PMID:30987996]. Apoptotic signaling is negatively regulated by decoy receptors (TRAIL-R3, TRAIL-R4), the caspase-8 inhibitor FLIP, and TRAF2, while TRAIL-R4 additionally activates NF-κB [PMID:9242610, PMID:9430226, PMID:25299769]. Beyond apoptosis, TRAIL signals non-apoptotically through ERK to regulate erythroid differentiation, through TAK1–AMPK to induce cytoprotective autophagy in normal epithelial cells, and through nuclear TRAIL-R2 trafficking to inhibit let-7 miRNA maturation [PMID:12969966, PMID:19197243, PMID:31416165]. TRAIL gene expression is transcriptionally controlled by FOXO factors (via the PI3K–PTEN–Akt axis), NF-κB, interferon-response elements, and Sp1 (recruited upon HDAC inhibitor treatment), and is induced in astrocytes by IFNγ from meningeal NK cells to limit CNS inflammation via T cell apoptosis [PMID:12351634, PMID:15619633, PMID:18701496, PMID:33408417].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Identification of TRAIL as a TNF-family cytokine that induces apoptosis in transformed cells answered the question of whether the TNF superfamily contained additional death ligands with tumor-selective activity.\",\n      \"evidence\": \"cDNA cloning and recombinant soluble protein apoptosis assays across diverse tumor lines\",\n      \"pmids\": [\"8777713\", \"8663110\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cognate receptor(s) unknown\", \"Mechanism of tumor selectivity unexplained\", \"In vivo physiological role not yet addressed\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Rapid identification of four TRAIL receptors (DR4, DR5 with death domains; TRAIL-R3 and TRAIL-R4 as decoy/modulatory receptors) established a combinatorial receptor system governing differential cell sensitivity to TRAIL.\",\n      \"evidence\": \"Receptor cloning, binding affinity measurements, death domain functional assays, ectopic expression protection experiments, NF-κB reporter assays across multiple independent laboratories\",\n      \"pmids\": [\"9082980\", \"9311998\", \"9242610\", \"9373179\", \"9430226\", \"9325248\", \"9314565\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Proximal signaling adaptors at the DISC not yet defined for TRAIL receptors\", \"Relative contributions of DR4 vs DR5 in different tissues unknown\", \"Whether DR4 uses FADD was disputed across early studies\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstration that FADD, TRADD, and FLIP regulate TRAIL receptor signaling, and that DR4 and DR5 can form heterocomplexes, established the proximal adaptor framework for TRAIL-induced death signaling.\",\n      \"evidence\": \"Co-immunoprecipitation of FADD/TRADD with TRAIL receptors, dominant-negative FADD and FLIP overexpression blocking apoptosis\",\n      \"pmids\": [\"9430228\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether caspase-8 is recruited directly to the native DISC not yet shown\", \"Stoichiometry of DISC components undefined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"The crystal structure of the TRAIL trimer–DR5 ectodomain complex revealed the molecular basis of ligand–receptor interaction, showing three DR5 molecules bound in crevices between TRAIL monomers.\",\n      \"evidence\": \"X-ray crystallography of Apo2L/TRAIL–DR5 complex\",\n      \"pmids\": [\"10549288\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of full-length receptor or intracellular DISC assembly\", \"Structural basis for decoy receptor competition not resolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Native DISC immunoprecipitation combined with FADD- and caspase-8-deficient cells proved that both FADD and caspase-8 are essential and independently recruited components of the TRAIL DISC, resolving earlier conflicting data.\",\n      \"evidence\": \"Native DISC precipitation from ligand-stimulated cells; FADD-deficient and caspase-8-deficient Jurkat genetic knockouts\",\n      \"pmids\": [\"10894160\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Post-translational regulation of caspase-8 at the DISC unknown\", \"Role of caspase-10 not yet clarified\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Multiple discoveries established transcriptional control of TRAIL: FOXO factors bind the TRAIL promoter (linking PI3K–PTEN–Akt to TRAIL expression), NF-κB and interferon-response elements also regulate transcription, and caspase-10 was shown to be recruited to the DISC in a FADD-dependent but caspase-8-non-redundant manner.\",\n      \"evidence\": \"Promoter reporter mapping (FKHRL1-responsive element at −138 to −121), adenoviral FOXO overexpression, caspase-10 native DISC immunoprecipitation and overexpression rescue in caspase-8-null cells\",\n      \"pmids\": [\"12351634\", \"12198154\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Additional transcription factors and chromatin regulators not yet identified\", \"Physiological role of caspase-10 in TRAIL signaling unclear\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"TRAIL was found to have non-apoptotic functions: ERK-dependent regulation of erythroid differentiation via TRAIL-R2, and differentiation induction (not apoptosis) in intestinal epithelial cells, expanding TRAIL biology beyond cell death.\",\n      \"evidence\": \"Pharmacological ERK/p38/JNK inhibitors in primary CD34+ erythroid cells; Fc-TRAIL-R2 chimera blocking in intestinal epithelial cells\",\n      \"pmids\": [\"12969966\", \"16245299\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream transcriptional targets of ERK in erythroid TRAIL signaling unknown\", \"Mechanism linking TRAIL-R2 to p21/p27 induction in gut epithelium not defined\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"HDAC inhibitors were shown to directly activate the TNFSF10 promoter in AML cells, and FLIP was confirmed as a potent DISC-level inhibitor of caspase-8 activation, establishing two pharmacologically actionable nodes in the pathway.\",\n      \"evidence\": \"Promoter reporter assays with HDAC inhibitors, RNAi dissection of TRAIL/p21/differentiation, FLIP overexpression and knockdown with caspase-8 processing readouts\",\n      \"pmids\": [\"15619633\", \"15110178\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the HDAC(s) that repress TRAIL transcription unknown\", \"Whether FLIP regulation differs between TRAIL-R1 and TRAIL-R2 DISCs not addressed\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"O-glycosylation of DR4/DR5 ectodomains by GALNT14 was identified as a determinant of TRAIL sensitivity, promoting ligand-induced receptor clustering and caspase-8 activation—answering why cells with equivalent receptor levels differ in TRAIL responsiveness.\",\n      \"evidence\": \"GALNT14 RNAi/overexpression, mass spectrometry glycan mapping of DR5, progressive mutagenesis of O-glycosylation sites, receptor clustering assays\",\n      \"pmids\": [\"17167167\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full set of glycosyltransferases modifying DR4/DR5 not catalogued\", \"Structural mechanism by which O-glycans promote clustering unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Two key post-translational mechanisms were uncovered: CUL3-mediated polyubiquitination of caspase-8 (reversed by A20, read by p62) drives caspase-8 aggregation for full activation; and TRAIL-induced TAK1–AMPK signaling triggers cytoprotective autophagy in normal cells, explaining their TRAIL resistance.\",\n      \"evidence\": \"CUL3/RBX1/A20/p62 RNAi with DISC IP and caspase processing assays; TAK1/LKB1/CaMKKβ RNAi with AMPK/mTORC1 epistasis in normal vs. transformed cells\",\n      \"pmids\": [\"19427028\", \"19197243\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific CUL3 substrate adaptor for caspase-8 not identified\", \"Whether p62-mediated aggregation occurs in all TRAIL-sensitive cell types unknown\", \"How TAK1 is activated by TRAIL receptors not mechanistically resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"TRAF2 was established as a negative regulator of both TRAIL-induced apoptosis and necroptosis, and nuclear TRAIL-R2 was shown to inhibit let-7 miRNA maturation via the Microprocessor complex, revealing a non-canonical nuclear signaling function.\",\n      \"evidence\": \"TRAF2 siRNA with RIP3 reconstitution and necrostatin-1; TRAIL-R2 NES mutagenesis, CRM-1 inhibition, co-IP with Microprocessor components, let-7 processing assays\",\n      \"pmids\": [\"25299769\", \"25165876\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of TRAF2 recruitment to the TRAIL DISC not defined\", \"Nuclear TRAIL-R2 findings based on limited cell types; generalizability unclear\", \"Physiological significance of let-7 regulation by TRAIL-R2 in vivo not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"O-GlcNAcylation of DR4-Ser424 was identified as essential for DISC and necrosome formation, discriminating DR4 from DR5 signaling and linking metabolic status (glucose levels) to TRAIL sensitivity.\",\n      \"evidence\": \"OGT knockdown, DR4-S424 site-directed mutagenesis, DISC/necrosome co-IP, receptor clustering assays, cancer patient mutation screen, glucose modulation\",\n      \"pmids\": [\"30987996\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other death domain residues are O-GlcNAcylated not surveyed\", \"In vivo validation of glucose-dependent TRAIL sensitization lacking\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"TRAIL expression in LAMP1+ astrocytes, driven by IFNγ from meningeal NK cells and modulated by the gut microbiome, was shown to limit CNS inflammation by inducing T cell apoptosis—establishing a physiological immune-regulatory role for TRAIL in vivo.\",\n      \"evidence\": \"CRISPR-Cas9 in vivo perturbation of astrocytic TRAIL, scRNA-seq, germ-free mouse models, TRAIL-DR5 blocking\",\n      \"pmids\": [\"33408417\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether astrocytic TRAIL has non-apoptotic signaling effects on T cells unknown\", \"Specific gut microbial taxa driving meningeal NK IFNγ not identified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the identity of the CUL3 substrate adaptor that ubiquitinates caspase-8, the structural basis of TRAIL-induced receptor clustering, the full spectrum of non-apoptotic TRAIL signaling outputs in different tissues, and the in vivo relevance of nuclear TRAIL-R2 in let-7 regulation.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CUL3 substrate adaptor for caspase-8 ubiquitination unidentified\", \"No full-length TRAIL receptor structure with intracellular domain\", \"Tissue-specific balance between apoptotic and non-apoptotic TRAIL signaling not systematically mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 10, 17]},\n      {\"term_id\": \"GO:0090729\", \"supporting_discovery_ids\": [0, 1, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 34]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 34]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 1, 11, 12, 21, 29]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [32, 37, 38]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 7, 22, 24]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [20, 26, 27]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"TNFRSF10A\",\n      \"TNFRSF10B\",\n      \"TNFRSF10C\",\n      \"TNFRSF10D\",\n      \"FADD\",\n      \"CASP8\",\n      \"CFLAR\",\n      \"TRAF2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}